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Fetal liver progenitor cells are the most natural precursors of hepatocytes and bile duct 
cells. They hold tremendous promise in their ability to provide a continual source of cells 
for cellular transplantation, bioartificial assisted liver devices, gene therapy for metabolic 
disorders, drug testing in pharmaceutical industries and even for studies in understanding 
mechanisms regulating normal liver development, specification and maturation.  
We thus aimed to isolate and characterize the population of progenitor cells from fetal 
liver and determine their role as a stem cell for liver repair and regeneration.  
Mid-trimester human fetal livers were cultured up to 3 months to allow enrichment of 
progenitor cells. A novel technique combining chemical selection with GS418 and 
mechanical harvesting was designed and successfully isolated these cells. Progenitor cells 
are small cells (10um) with high nuclear-cytoplasmic ratio of 46 hour doubling time. In 
optimized cultures on NIH 3T3 (mouse embryonal fibroblasts cells) feeder layers, clonal 
colonies validated by Humara X assay could be maintained up to 100 population 
doublings or 20 passages.   
Progenitor cells were then characterized by immunofluorescence, western blot and RT-
PCR. They had markers consistent with a stem cell signature including CD34, thy-1, c-kit 
and SSEA-4. They appeared to have a mixed epithelial-mesenchymal phenotype being 
positive for EPCAM, CK18, CK19 as well as vimentin and CD44. Interestingly they had 
yet to specify into hepatic fate as they were negative for albumin and alphafetoprotein, 
iv  
and do not express HNF transcription factors specific for hepatic lineage.(HNF1α,3β and 
4α). 
Progenitor cells were able to differentiate to become hepatocytes and cholangioytes via 
mesenchymal-epithelial transition. Hepatocytes were positive for albumin, Hep-par and 
alpha-1-antitrypsin and showed consistent features on electron microscopy. Functional 
studies including albumin secretion, glycogen storage, P450 enzymes inducibility and 
glucose 6 phosphastase activity were also positive. Cholangiocyte differentiation was 
correspondingly determined with positivity for CK7, CK19, GGT and characteristic 
microvilli on electron microscopy. Differentiation into mesodermal lineages was also 
successful with lineage confirmed with at least 2 modalitites. Fat differentiation was 
positive for oil globules and PPARgamma RTPCR; cartilage differentiation was 
confirmed with identification of collagen II and mucopolysaccharides; bone 
differentiation was confirmed with calcium deposition and osteopontin RTPCR and 
endothelium differentiation confirmed with identification of VWF and CD31. 
 Progenitor cells were transplanted into Rag2γc double knockout mice treated with 
retrorsine and carbon tetracholoride. Successful engraftment, integration and function of 
transplanted human cells was determined with human specific albumin, Hep-Par and ZO-
1  immunofluorescence, RT PCR of liver samples, ELISA of mice serum and in situ 
hybridization for human chromosome. Transplantation up to 9 months showed prolonged 
though variable survival with no evidence of fusion or aneuploidy. 
These progenitor cells exist in fetal liver de novo and using lineage tracing, do not appear 
to have been derived from hepatocytes, MSC or HSC cells. Given their mixed phenotype, 
v  
they may have arisen from mesendoderm This is the first reported long term culture of 
clonal population of human fetal liver progenitor cells fulfilling stem cell properties of 
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Liver cirrhosis and end-stage liver failure constitute a major cause of mortality and 
morbidity worldwide. There are currently 400 million Hepatitis B carriers in the 
world, of which 1 million die every year from its complications.1-2 Hepatitis B is 
endemic in Singapore with up to 4% of the population being carriers of the virus3. In 
the west, chronic Hepatitis C will reach epidemic proportions in the next 2 decades. 
When end stage liver cirrhosis develops, the only cure lies in liver transplantation. 
However, the scarcity of suitable organ grafts has resulted in an exponential increase 
in the waiting list for liver transplant worldwide. Patients are waiting longer for a 
transplant and more patients are dying while on the waiting list4.  
  
The promise of regenerative medicine has led to significant advances over the last two 
decades in the understanding of stem/progenitor cell and spurred interest in trying to 
obtain liver cells in vitro for therapeutic application. In fact, the liver is an organ with 
tremendous regenerative potential.  Liver hepatocytes can repair and regenerate itself 
when the liver is injured or after liver resection surgery. When the injury is severe and 
normal hepatocytes can no longer regenerate the liver, a distinct progenitor cell 
compartment is activated to attempt to repair and regenerate the liver5.  
 
Yet hepatocytes, despite their innate regenerative potential have very limited use in 
this respect as they are notoriously difficult to grow in culture and they dedifferentiate 
rapidly, losing their hepatocytic functions.  As a result, progenitor/ stem cells hold 
tremendous promise as they can potentially provide a continual source of cells for a 
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variety of therapeutic uses.  These uses include  cellular therapy where cells are 
transplanted directly into patients with liver failure6, gene therapy for rescue of 
genetic or metabolic disorders7 or employed in bioartificial liver device for liver 
dialysis8, especially where liver transplant is not available or possible. In addition, 
large numbers of human hepatocytes are needed for toxicology studies for drug 
development in the pharmaceutical industry and even for studies in understanding 
mechanisms regulating normal liver development, specification and maturation. 
(Figure 1)  
As a result of stem cells being the potential answer to these unmet needs, there has  
been significant efforts to identify and utilize stem cells that can be expanded easily in 
culture and subsequently manipulated to give rise to hepatocytes, either by directed 
differentiation (hepatocyte linage stem/ progenitor cells) or transdifferentiation  (stem 
cells from other lineages).9  
1.1 Definition Of A Stem Cell 
Potten and Loeffler10 describe stem cells as undifferentiated cells capable of: (i) 
proliferation; (ii) self-maintenance; (iii) the production of a large number of 
differentiated, functional progeny; (iv) regenerating the tissue after injury; and (v) 
flexibility in choice of these options (i.e. plasticity) (Table 1). Stem cells can be 
further classified into pluripotent or multipotent stem cells by virtue of how primitive 
they are.  
Progenitor cells, a term often used interchangeably with stem cells is generally 
accepted to refer to descendants of stem cells.11 Progenitor cells are still highly 
proliferative and can differentiate into specialized cells but they cannot self-regenerate 
and are less plastic compared to stem cells. Adult stem cells, particularly those 
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derived from specialized tissues, should strictly be called progenitor cells until they 
fulfill the strict definition of a true stem cell. A paradox then exist such that stem cells 
that are totipotent with the highest proliferative potential to scale up, have the highest 
risks of oncogenicity limiting their transition to clinical use. Stem cells which are 
committed tissue specific cells have lower tumorigenic risk but are less plastic and 
may have limited regenerative potential limiting their ability to scale up. (Figure 2) 
1.2 Potential Liver Stem Cell candidates 
The fledging field of liver stem cells has, however, been dogged by two major 
problems: (i) inconsistencies in the immunophenotype of liver progenitor cells; and 
(ii) lack of understanding of the true physiological role of variously described 
stem/progenitor cell populations, especially stem cells derived from extra-hepatic 
transdifferentiation or from protocols that require unconventional prolonged culture.  
1.2.1 Hepatocytes 
Interestingly, hepatocytes are the main cell that undergoes mitosis and repair of the 
liver in most liver injury including surgical resection of the liver12-13.  While they are 
dormant in normal state with as few as one out of 2000-3000 differentiated adult 
hepatocytes dividing to maintain the physiological liver mass, they can undergo 
division up to 100x when activated5. In fact, they can give rise to biliary type 
epithelium14  in injury.  Transplantation of mouse adult hepatocytes showed that they 
are able to engraft into urokinase-type plasminogen activator-transgenic (uPA) mice, 
undergoing more than 70 replications,  repopulate the recipient liver, and even be 
serially transplanted fulfilling one of the key characteristics of a stem cell15. They can 
also repopulate injury animal model where up to 90% of uPA-Severe Combined 
Immunodeficiency (SCID) mice liver can be repopulated with human liver cells  
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under severe selection pressure and immunosupression16. Their limited ability to 
expand in vitro however, limits their clinical usefulness as healthy liver grafts from 
which they can be derived are limited and any use of liver graft for cellular 
transplantation will further compound the problem of graft shortage.  
1.2.2 Intrinsic Liver Progenitor Cells 
Work in rodents by Fausto17, Sell18 and others showed that, in animal models of liver 
injury where the proliferation of the resident hepatocytes was inhibited, a progenitor 
population of oval cells was activated and can be identified as “oval cells” population. 
Models of injury that can activate and expand this population of cells utilises the 
principle of inhibiting replication of the resident hepatocyte and providing a 
regenerative stimulus through liver injury. These strategies include combinations of  
chemical injury, such as retrorsine19, 2-acetylaminoflurene (AAF)20, carbon 
tetrachloride21, galactosamine22; dietary models such as choline-deficient diet23, 3,5-
diethoxycarbonyl-1,4-dihydrocollidine (DDC)24  and/or its modification with 
ethionine supplementation25 and partial hepatectomy20.  
 
These oval cells, with slight variations between species, are positive for albumin, 
alpha-fetoprotein (AFP), cytokeratins (CK) 7, 8, 18 and 19 as well as progenitor 
markers such as OV6 (rat), A6 (mouse) and G75. These cells have been shown to be 
bipotential in both in vitro and in vivo setting to be able to give rise to both 
hepatocytes and bile duct epithelium.26-28. Other markers that have been reported  
include  hematopoietic markers such as CD34, C-kit, Sca-1 and CD90 (thy-1), as well 
as AC-133.29-31  Even mesenchymal markers such as CD44 and even vimentin have 
been described32. The variability of markers have called into question of issues such 
as interspecies variation,  non-clonal cultures, culture artefacts32-33; or in the latter 
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case, true mesenchymal–epithelial transdifferentiation34.  Newer studies on these 
progenitor cells have identified new surface markers that allow flow sorting of these 
cells to form colony forming units, a concept similar to hematopoietic stem cells.35 
Over the last few years, evidence has emerged that these oval cells can be isolated 
from normal adult liver without injury stimulus36-37 lending evidence to the de novo 
entity of progenitor stem cells in adult liver.38   
 
The equivalent progenitor cells in adult human liver have been localised to the 
terminal bile ductules, known as canals of Hering, near the portal triads in zone 1 of 
the hepatic acinus39. They are believed to be a dormant cell compartment and are 
activated when the adult hepatocytes are not able to repair and regenerate the injured 
liver. They are believed to play a role in liver repair in liver diseases such as alcoholic 
liver disease, fatty liver, viral hepatitis or fulminant hepatic failure40-41.  They 
proliferate and give rise to two distinct lineages: ductular daughter cells appear as 
ductular hyperplasia while hepatocytic lineages show progressive differentiation 
along a linear pathway42.  More recent success utilizing EPCAM and NCAM have 
reported the isolation of a population of cells from normal or cirrhotic liver that have 
bipotential differentiation capacity43-44. They were able to repopulate animal models 
of liver injury and are negative for albumin and AFP but positive for CD44, NCAM, 
claudin and AC133.  
 
1.2.3 Fetal Liver  
Knowledge on fetal liver progenitor cells has come mainly from work on rodent fetal 
livers. Hepatoblast cell lines have been derived from embryonic age ED12 rat45 and 
ED9.5 mouse embryonic livers46. These cells are albumin, AFP, and CK19 positive, 
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and as expected, have bipotential differentiation capability. Various approaches have 
been attempted to isolate these progenitor cells by positive selection, negative panning 
or by culture selection. Suzuki et al47 used fluorescent activated sort and reported that 
the CD45–TER119–CD49f+/lowCD29+CD117–c-met+ fraction gave rise to the 
highest number of colony forming units. Strick-Marchand et al28 isolated a bipotential 
mouse epithelial line from fetal livers. These cells, like those from Suzuki et al47, 
were able to give rise to both hepatocyte and biliary epithelium in vivo.  Using the 
fetal pig model, Talbot et al were able to derive hepatocytes from 8 day epiblast48. 
 
Using human fetal livers, Malhi et al49 isolated fetal liver cells that could be 
cryopreserved, were bipotential and could repopulate the liver of animal models of 
liver disease. Lazaro et al50 was able to maintain long term cultures of primary fetal 
livers. In their culture, they saw a subpopulation of progenitor cells which they 
suggested to be fetal liver stem cells. Nowak et al51 selected CD117+/CD34+/Lin- 
cells from fetal livers and showed they had similar in vitro and in vivo bipotential 
capability. Schmelzer et al44 used EPCAM to sort and isolate progenitor cells and 
estimated that these cells constituted 2-5% of the mid-trimester fetal livers.   
   
 The potential of these rodent fetal progenitor cells can be glimpsed from repopulation 
models where cryopreserved fetal hepatoblasts transplanted into normal adult livers 
were able to achieve repopulation of up to 14%, even with no selection pressure.52  
This has tremendous implications for gene therapy for metabolic defects and end 
stage liver diseases. 
 
 




1.2.4 The Embryonic Stem Cell  
Embryonic stem cells from the inner cell mass of embryos can be coaxed into the 
endodermal lineages using a variety of culture technique. These cells can be in turn, 
differentiated into functional hepatocytes fairly efficiently with both in vivo and in 
vitro techniques53-54 including  variations of serial differentiation protocol of sodium 
butyrate (human ES cell)55, activin, FGF2, BMP-2, HGF and oncostatin M (human ES 
cell)56-57 and/or coculture with fetal thy-1 mesenchymal cells58, human liver non-
parenchymal cell lines59 or mature hepatoctes60.  
 
Differentiated cells can produce AFP, transferrin and albumin61-63. Transplantation of 
these cells in murine models of liver injury showed successful engraftment64-68  with  
efficiency ranging from 0.06% to 2%. Clinical improvement in the levels of albumin 
and bilirubin were measurable with ES cell–derived hepatocyte transfusion61, 63-64. In 
addition, survival benefits were demonstrable with reversal of acute liver failure when 
embryonic derived hepatocytes were incorporated in  bioartificial liver devices 
transplanted subcutaneously  into mice subjected to 90% hepatectomy69 or 
administered as  extracorporeal liver dialysis60 in rats treated with galactosamine.  
 
Despite these encouraging successes, ES cells derived hepatocytes have been reported 
to have limited functionality and maturation67. Other challenges include the ability to 
generate sufficient numbers of differentiated cells for transplant, the ethical concerns 
of using blastocyst in their derivation. More importantly, the concerns with teratoma 
formation remains a formidable challenge. While  removal of undifferentiated ES 
cells (Oct3/4 positive) before transplantation significantly decreased the teratoma 
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formation66, it is possible that a single residual ES cells transplanted into the body will  
eventually give rise to a teratoma62, 64. 
 
1.2.5 Induced Pluripotent Stem Cell   
Induced pluripotent stem (iPS) cells are generated from reverse reprogramming of 
somatic cells of individuals by using defined transcription factors70-72. These cells are 
reported to be similar to ESCs and can be differentiated into hepatocyte lineage cells 
using similar protocols.  These cells demonstrated liver cell functions including 
albumin secretion, glycogen synthesis, urea production and inducible cytochrome 
P450 activity and were comparable to that of the human ES cell-derived hepatic cells. 
They could also be transplanted into animal models and shown to engraft in the liver. 
73-75. The obvious advantage of these cells are that they can be derived autologously 
from the fibroblast of the same patient thus obviating the need for immunosuppression 
as well as being free from the ethical concerns of ES cells. However concerns with 
teratoma formation and  lentivirus use still need to be overcome.  
 
1.2.6 The Bone Marrow Hematopoietic Stem Cell (Table 3) 
The promise of bone marrow stem cell as a candidate for liver regeneration was first 
fueled by initial reports of hepatocytes having a bone marrow origin as liver cells of 
female patients who had received male bone marrow transplants were found to 
contain XY sex chromosomes76-77. The first case of proof that these bone marrow 
stem cells can repopulate an injured liver was shown by Lagasse et al78, using the 
hereditary type I tyrosinemia (FAH) model which exerts an extreme selection 
pressure on bone marrow cells. However, this repair process was subsequently shown 
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to be primarily mediated by fusion with the monocyte subpopulation and not 
transdifferentiation of bone marrow stem cells79.  
 
On the other hand, Harris et al80 used a sophisticated cre/lox system to show that it is 
possible to find epithelial cells derived from bone marrow with no evidence of fusion. 
Since then, many studies and critical reviews81,82-85  have pointed out that, although it 
is possible to transdifferentiate bone marrow stem cells to produce hepatocyte-like 
cells, the weight of evidence suggest that most transdifferentiation phenomena are due 
to fusion events. Further, this process contributes only minimally to liver regeneration 
and, in the absence of continued overwhelming selection pressure, is rapidly lost. 
Although there is still controversy over whether transdifferentiation of bone marrow 
cells can occur in vivo without fusion, depending on the model used80, 86, it is fair to 
conclude that, to date, there is no conclusive evidence that hematopoietic stem cells 
play an important physiological or pathological role in liver injury and repair via 
transdifferentiation5, 87.  
 
1.2.7 The Umbilical Cord Stem Cell (Table 3)  
Arising from the excitement that hematopoietic stem cells can become hepatocytes, 
umbilical cord blood became the next potential candidate. Indeed, many groups have 
reported successful generation of hepatocytes from the umbilical cord blood.  In vivo 
liver repopulation has been shown in in CCl4 , 2AAF and Fas ligand (Fas-L) liver 
injury models88-90. However, the true stem cell fraction, whether it is the 
hematopoietic, mesenchymal or a distinct somatic progenitor population in cord 
blood, has not been defined. Both CD34+ and CD34- populations were reported as 
able to give rise to “hepatocytes”91. While mesenchymal stem cell fraction was 
  Page 10  
 
 
specifically studied 92-94 as being the candidate liver precursor cells in some studies, 
others reported that fractions defined by beta2microglob+/c-met+89, CD34+/lin-95  
and C1qRp90 harbored the pluripotent stem cell.  
 
Survival benefit has been claimed in rodent studies96, but more interestingly, similar 
transplantation experiments in mammals such as fetal sheep97 and goats95, have also 
shown promise. Almeida-Porada et al97  described multipotent cells derived from 
human cord blood and were able to create a chimeric model in preimmune fetal sheep 
where human hepatocytes constituted as much as 20% of the liver 11 months after 
transplantation. Like the bone marrow story, cell fusion has been implicated as the 
mechanism by which human cells are seen in the recipient’s liver. Yet in studies 
specifically looking at cell fusion, reports have been conflicting; some observed cell 
fusion in most cells98, some claim no evidence of cell fusion,99 and yet others 
observed both scenarios100.   
  
1.2.8 The Mesenchymal Stem Cell (Table 3) 
Mesenchymal stem cells derived from bone marrow or fetal liver have been shown to 
differentiate into liver cells in both in vitro and invivo experiments.101-105. Aurich et 
al102 differentiated mesenchymal stem cells from human bone marrow into 
hepatocytes using pro-hepatocytic growth medium, and transplanted these cells into 
Rag2 mice. The engrafted cells continued to express human liver specific functions 
and showed no evidence of fusion.  It is interesting that liver stem cells have been 
increasingly reported to carry both endodermal and mesenchymal markers32. A 
multipotent progenitor cells from the bone marrow, termed MAPCs have been 
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reported to by able to differentiate into hepatocytes as well as a wide variety of other 
cell types.106-107 
 
Multiple reports have claimed that bone marrow mesenchymal cells when 
transplanted into animal models of liver cirrhosis, ameliorate and reverse the disease. 
6, 108.  It is not known, however, whether other mechanisms may be at play that might 
prove useful in bone marrow mesenchymal therapy for injured liver Sakaida et al6 
reported improvement of liver cirrhosis claiming both reduction in fibrosis due to 
MMP-9 expression and transdifferentiation into hepatocytes81. Similar studies also 
lend support to the contention that bone marrow-derived cells, especially the 
mesenchymal stem cell component can enter the fibrous bands in cirrhotic liver 
models and aid in regression of fibrosis109-110. Yet other studies have found no benefit 
from these bone marrow mesenchymal stem cells111 and some have even cautioned 
that bone marrow contributes significantly to hepatic stellate cell and myofibroblast 
population in the liver. If such is the case, it  may also participate in and accelerate the 
fibrotic process.112-113  
Arising from the promising data in animals, bone marrow or peripheral stem cells 
were transplanted into human patients with cirrhosis or acute liver injury. 114-117 and 
significant improvement in liver child pugh score or functions were reported. While 
there was data suggesting that there was improved liver proliferation and repair, it 
could not be ascertained if the effect was due to mesenchymal cells differentiating 
into hepatocytes or a immunomodulatory reparative effect of the trranpslanted cells 
on native hepatocytes. To support the latter hypothesis, there have been several 
publications118-119 supporting the role of mesenchymal cells as repair assist cells and 
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perhaps conditioned medium from the mesenchymal stem cells may be sufficient to 
aid liver repair. 
1.2.9 The Adipose Tissue Mesenchymal Stem Cell (Table 3) 
In addition, mesenchymal lineage stem cells such as adipose tissue derived stem cells 
have also been coaxed to form hepatocyte-like cells120-123.124. These cells appear to be 
similar to mesenchymal stem cell yet are easier to convert to functional hepatocytes 
and have better liver function. This obviously opens up the possibility of autologous 
transplantation as adipose cells can be obtained from the same patient with liver 
failure.  
 
1.3 The Developing Human Liver  
The liver bud is formed from the ventral wall of the endoderm around D20 of 
gestation125. Receiving FGF and BMP signals from the heart and septum transversum, 
it specifies for hepatic lineage and invaginates the septum transversum. It is believed 
that the endodermal cells differentiate to form hepatoblasts which are bipotential and 
further differentiate to form hepatocytes and bile ducts along the ductal plates126. 
Mesodermal cells from the septum transversum form the non-parenchymal fraction 
including endothelial cells, fibroblasts and stromal cells. In addition, hematopoietic 
stem cells colonize the liver and reside in the liver through most part of the gestation 
period, leaving for the bone marrow when the liver matures and is no longer 
conducive for hematopoiesis127. A tight interactive paracrine regulation thus exist 
between hepatoblast, mesenchymal cells, hematopoietic cells and extracellular matrix 
driving survival, proliferation and differentiation of the various lineages that 
constitute the liver.  
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1.4 Current Knowledge on Human Fetal Liver Progenitor Cells.  
At the point of initiating this project and perhaps even to date, true human liver stem 
cells have not been isolated and their characteristics and physiological roles are 
hitherto, unknown.  
 
Human fetal liver progenitor cells have several advantages over other stem cell 
sources. The progenitor cells in the adult liver are hypothesized to be similar to fetal 
progenitor cells which are remnants of the developing embryonic liver trapped in their 
“progenitor” niche. Although adult progenitor cells are plentiful in advanced liver 
disease, the accumulation of DNA mutations128 and shortening of telomeres in these 
adult cells means their equivalent counterpart in the fetal liver is more attractive as the 
ideal stem cell candidate for cell therapy applications. In addition, fetal liver 
progenitor cells have committed to the liver lineage and are further downstream in the 
differentiation process compared to the more pluripotent ES cell. As such, they would 
be technically easier to differentiate into fully functional cells with lower risks of 
teratoma or malignant transformation129. Last but not least, fetal liver stem/progenitor 
cells are the natural putative cells that give rise to the adult liver during physiological 
development of the human liver.  Systematic understanding of the physiological 
mechanisms and changes that control this physiological differentiation of fetal liver 
progenitor cells to differentiated cells is critical in allowing us to manipulate in vitro 









The distinct population of putative liver stem cells in the adult liver arose during fetal 
development and represents a unique subpopulation in the fetal liver. Derived directly 
from the endodermal layer, these stem cells self-regenerate and transit into 
hepatoblasts before differentiating into mature hepatocytes and biliary cells. While 
dormant in the adult liver unless activated in injury, these cells would be actively 
replicating and readily identified in the normal fetal liver when the liver bud is 
expanding to form the organ. These cells would be more committed and would be 
easier to differentiate into functional hepatocytes and bile duct cells but yet retain 
self-regenerative potential to allow scale up in vitro. They would have lost their 
totipotency but be less likely to be oncogenic and thus be more useful in transition to 
clinical applications.   
 
By identifying these cells in fetal liver and studying their characteristics, it would be 
possible to isolate them using sorting techniques based on their surface molecular 
signature. The ability to maintain these cells in vitro would allow expansion of these 
cells yielding full characterisation of their self regenerative capacity, plasticity and 
potential to differentiate into functional cells both in vitro and in vivo.  Studying these 
unadulterated physiological stem cells from the fetal liver will yield important 
understanding of the environment cues that control stemness as well as differentiation. 
This knowledge can then be applied in vitro to other stem cell candidates or during 
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1.6 Overall Aims of Study 
The specific aims of the study are thus:  
1) To identify, isolate and purify the liver progenitor population in the human 
fetal liver for characterisation.  
2) To expand fetal liver progenitor cell, demonstrating self proliferative potential 
and determine the ideal in vitro culture conditions.   
3) To demonstrate precursor- progeny relationship – potential for differentiation 
into at least 2 tissue types -  hepatocytes, bile duct cells as well as exploration 
of their plasticity. 
4) To determine functional capabilities of progenies of hepatocytes and 
cholangiocytes from these progenitor cells. 
5) To demonstrate in vivo functions of these progenitor cells - transplantability, 
durability of transplant and potential for serial transplantation. 
 
 














Isolating the Human Fetal Liver Stem Cell  
 
Long term fetal liver cultures reported by Lazaro et al50 have raised the possibility of 
a distinct cell population that became prominent after 1- 3 month of culture. These 
cells had high nuclear-cytoplasmic ratio and a higher replication rate than 
hepatoblasts and were suggestive of blast cell population.  
 
However fetal liver stem cells have never been isolated and little is known about their 
immunophenotype, culture conditions and growth potential. As such, to determine 
that these were indeed stem cells, strategy was undertaken to allow these cells to 
enrich in primary fetal culture and expand to sizeable numbers. Attempts will then be 
made to purify these cells for characterisation and systematic exploration of ideal 
culture conditions.  
 
2.1 Expansion of  progenitor cell in primary hepatic cultures  
We observed the growth of “blast” cells in their native state in primary hepatic 
cultures and maintained them up to 6 months. (Figure 2.1) 
 
In primary cultures at density of 10^4 cells per cm2, the plate became confluent 
within a week with a predominant mixed population of small and large hepatocyte 
colonies.  Interspersed in between these colonies were non-parenchymal cells such as 
ductal biliary cells, fibroblasts and endothelial cells. Hematopoietic cells were 
constantly formed from the hematopoietic stem cells in culture and despite washing 
and changes in medium, persisted till second week before they disappeared. Among 
the hepatocytic cells, clusters of small dense cells started to appear by D3 to 5 in 
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cultures. In the initial first 2 weeks, they became more prominent as they were 
proliferating faster than the hepatocytes. These cells had high nuclear cytoplasmic 
ration and had been shown previously to have higher BrdU staining. (Figure 2.2)  
 
By about 3 weeks, the mesenchymal fraction started to increase and overgrow the 
epithelial cells forming a meshwork of multilayered cells. While some of the 
epithelial cells die off, a new population of small distinct high-nuclear-cytoplasmic 
ratio cells forms on top of the multilayered cultures and became confluent by about 6 
weeks. Interestingly, a distinct increase in the viscosity of the culture supernatant is 
always noted to precede the expansion of these progenitor cells. Although not tested, 
it was believed that the viscosity was due to extracellular matrix secreted by non-
parenchymal cells. 
 
2.2 Isolation  
To isolate the progenitor cells, 3 month cultures with confluent blast cells were 
dissociated and passaged. As these epithelial cells were extremely sticky and formed 
tight junctions, dissociation by breaking them up into small individual cells was 
extremely difficult. Of the variety of dissociation techniques employed, the ideal 
dissociation was the protocol of collagenase with dispase dissociation for 30 min 
interspersed with mechanical disruption. Adding cold trypsin increases the efficiency 
yield but dropped the viability of cells. (Table 2)    
 
2.3 Purification technique 
Once cells were dissociated into single or small 2-3 cell clusters, they were purified 
with a variety of techniques.  




2.3.1 Flow cytometry  
Sorting was performed separately using c-met and CD 34 antibodies and secondarily 
labeled with Alexa 488 and controlled with similar idiotype and propidium iodide. . 
Flow cytometry sorting resulted in 10^4 cells from 12 million cells and were cultured 
at intermediate density at 10^3 cells/cm2. Sparse intermittent cells were seen 
attaching at Day 3 but expanded over 2 weeks after plating. They showed a bizarre 
morphology with spindle shaped and flattened cells initially that reorganized to 
epitheloid configuration. Eventually however, fibroblast overgrew the plate. As cells 
had to be broken down to single cells before flow sorting, most of the epithelial 2-3 
cell clumps were filtered off resulting in significant loss of cells. Majority of the 
single cells that were sorted did not attach and were not viable in culture.  In addition, 
uncertainty over the changing morphology of the cells and risks of contamination 
from a Flow Activated Cytometry Sorting resulted in abandonment of this 
technique.(Figure 2.3) 
 
2.3.2 Chemical isolation 
In direct passage or subculture of enriched primary fetal hepatocyte cultures,  
epithelial blast cell clusters expanded seemingly from clonal origin amidst the 
fibroblast non-parenchymal cells. With time however, fibroblast again overgrew the 
cultures. Chemical selection was thus attempted by testing cultures with proline130 and  
geneticin131 to inhibit fibroblast growth. Of the methods used, geneticin had the best 
effect at 50ng/ml when at D5-7, fibroblasts showed apoptotic cell death leaving 
behind viable blast cell colonies. Persistence of geneticin or stronger dose of geneticin 
resulted in delayed but eventual death of blast cell colonies as well. Withdrawal of 
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geneticin at D7 resulted in survival of blast cell colonies but they undergo 
spontaneous differentiation with increase in cytoplasm and assumption of hepatocyte 
like morphology and immunophenotype. These differentiated cells drop in their 
replication rate compared to their parent “blast cells” and eventually senesce. (Figure 
2.4) 
  
It thus appeared that fibroblasts may be acting as a feeder layer allowing for clonal 
expansion of the progenitor cells. Geneticin was more toxic to the fibroblast than 
progenitor cells and thus at D7, resulted in death of the fibroblast feeders while 
progenitor cells were still alive and can be salvaged by removing geneticin. However, 
the loss of the feeder layers resulted in spontaneous differentiation of these cells.  
 
2.3.3 Mechanical Isolation 
We thus postulated that within the window period of D5-D7 when feeder cells were 
inhibited, progenitor cells can be mechanically isolated using cut and paste technique, 
a technique we adapted over from ES cell cultures.  Using micro-surgical 
manipulation under an inverted microscope, colonies with “high quality stem cell 
morphologies can be cut into 4-5 cell clusters and lifted off and transferred to healthy 
feeder layers where they can survive and expand. Clusters of progenitor cells up to 
100 cells colonies can be obtained in 1-2 weeks and can be further propagated up to 
more than 20 passages.  (Figure 2.5) 
 
2.4 Ideal culture condition (Table 3) 
Human fetal liver progenitor cells behaved like Embryonic Stem cells. Cells at the 
periphery of the colony in direct contact with plastic expressed albumin and AFP and 
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showed spontaneous differentiation. Differentiated cells became hepatocytic like but 
decreased in replication rate and senesced after 2-3 weeks. To maintain them in 
progenitor state to maintain continued regeneration, the ideal culture conditions were 
systematically explored. Determination of regeneration and immunophenotype were 
performed at D7 using % of attachment, colony size increase, cell numbers with XTT 
assay,  morphology assessment and immunophenotype with EPCAM and CD44.  
 
2.4.1 Feeder layer/ Density:  
Fetal liver progenitor cells spontaneously differentiated when in low density cultures 
with cells taking on a bizarre large morphology. Progenitor morphology and 
immunophenotype is maintained only in center of clusters, As a result, congruous 
with ES cell cultures, feeder layers were used to provide the cell-cell contact as well 
as support of the progenitor cell cultures. Human fetal liver fibroblast, amniotic cells  
and mesenchymal stem cells were tested at densities from 10^3/cm2 to 10^6/cm2. 
Cultured progenitor cells were observed for morphology and immunophenotyped. 
Irradiated or mitomycin treated NIH3T3 cells (American Type Culture Collection, 
Manassas, VA) at 180,000 cells/cm2 were determined to be most supportive of 
progenitor cultures.  (Figure 2.6A, Figure 2.6C) 
 
2.4.2 Culture medium/Supplement  
Fetal liver culture medium as reported in Lazaro et al50 was adapted for progenitor 
cultures by removing dexamethasone, a component believed to enhance liver 
differentiation. As essential growth factors were not known, 20% serum FBS which 
contained most growth factors was added to cultures with complex fatty acids. bFGF 
was added at 20ng/ml fresh daily and was found to be critical in maintaining 
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progenitor cell morphology. In addition, conditioned medium from 6 month fetal 
cultures were essential to augment replication.  (Table 3) 
 
2.4.3 Extracellular matrix  
The optimal matrix that supported progenitor cell cultures was tested using laminin 
(5ug/ml), collagen (1:5), fibronectin (5ug/ml), gelatin (5ug/ml) and hyaluronic acid 
(Suplasyn, Bioniche Life Sciences Inc., London, Ontario, Canada).  Without feeder 
layers, laminin and hyaluronic acid maintained morphology and immunophenotype of 
EPCAM and CD44 up to 7 days. Collagen by itself resulted in differentiation of cells 
with acquirement of albumin expression by D3. Fibronectin and gelatin resulted in  
loss of morphology and immunophenotype. Hyaluronic acid maintained 
immunophenotype but resulted in biliary type morphology. With feeder layers, 
combination using sequential layering of collagen and laminin was determined to be 
the optimal matrix for attachment and maintenance of fetal liver progenitor cells. 
(Figure 2.6B) 
                                                                                                                                                                  
2.5 Interpretation 
As human fetal liver progenitor cells had never been isolated and reported, an 
extensive systematic study was carried out to determine the ideal conditions that 
supported optimal cultures of these cells. To obtain enough cells for study, we 
maintained primary cultures of these cells allowing progenitor cells to enrich in 
culture naturally. The primary culture method involved a complex culture system 
where non-mesenchymal cells formed a natural feeder layer and loss of hepatocytes in 
culture simulated an injury system similar to cirrhosis condition where these cells are 
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activated, presumably from growth factors and extracellular matrix from non-
parenchymal cells. 
 
The challenge however with primary culture technique was that the progenitor cells, 
being epithelial, formed very tight junctions and was extremely difficult to dissociate 
for isolation. Flow cytometry and magnetic sorting were designed for hematogenous 
single cells and were not optimal for epithelial cells as aggressive enzymatic 
dissociation resulted in death of these cells, stripping of antigen and compromised 
further culture of these cells. Progenitor cells attachment and growth kinetics were 
also better in clumps rather than isolated cells, a feature consistent with human ES 
cells.  
 
Subculture of these cells (passaging) allowed resolute expansion of these progenitor 
cells on the fibroblast feeder layers up to D9 but cultures are in turn overrun by the 
fibroblast and analysis was difficult. Use of chemical selection to inhibit fibroblast 
result in loss of feeder layer and spontaneous differentiation occur.  
 
To overcome these limitations, we designed a novel technique of chemical-
mechanical isolation. Relative inhibition of fibroblast with geneticin opened up a 
window period at D4-6 when progenitor cells are expanding and can be picked and 
transported to feeder layers and expanded. Using this technique, we were able to 
reliably harvest progenitor cells from >90% of our cultures, expand them for more 
than 20 passages and were the first to report successful isolation and culture of human 
fetal liver progenitor cells. 





























Method Duration Efficiency/ Viability 
Trypsin 10 min- 20 min +/ +  
Collagenase/ Dispase 10 min – 40 min ++ / ++ 
Trypsin/EDTA / collagenase 2/20 – 10/ 30 ++ / + 
Cold trypsin/ EDTA 4h-12h/ 30 min +/+ 
Cold trypsin/ EDTA/ 
collagenase/dispase/ 
30 min/ 10mins +++/ ++ 
collagenase/dispase + 
mechanical disruption 
30 min +++/ +++ 
 
Table 2: Comparing Different Dissociation Techniques And Their Efficiency In 
Breaking Up Cultures Into Single Cell And The Impact On The Viability Of 
Cells.  
 




Collagen +++ ++ Large cells +/- +++/- 
Laminin ++ +++ Maintained ++/++ -/- 
Fibronectin ++ + Lost -/++ +/- 
Gelatin ++ - Lost -/+ +/- 
HA + ++ Biliary  ++/++ -/+ 
Collagen/Lam +++ +++ Maintained ++/++ -/- 
Matrigel ++ +++ Large cells ++/++ +/- 
      
Amniotic 
Cells  
++ + Maintained ++/++ -/- 
NIH3T3 ++ ++ Maintained ++/++ -/- 
Fetal Liver 
fibroblast 
++ ++ Large cells +/- +++/- 
      
EGF  ++ Maintained ++/++ -/- 
FGF  ++ Maintained ++/++ -/- 
Dexa  + Large cells +/- +++/- 
Oncostatin  - Large cells +/- +++/- 
 
Table 3 Characterisation Of Ideal Culture Conditions For Human Fetal Liver 
Progenitor Cells. 




Extracellular Matrix Collagen (1:4 dilution coating)/ Laminin 5ug/cm2  
Feeder Layer NIH 3T3 (Irradiated or mitomycin treated) 10^3/cm2 
Medium 50% Fetal progenitor Culture medium 
       William’s E medium  
       High Glucose 
       Glutamine 
       Sodium pyruvate 
       Sodium bicarbonate 
       Ascorbic acid 
       Insulin-transferrrin and selenium + linoleic acid 
       Complex fatty acid 
       EGF 20ng/ml 
       bFGF 20ng/ml  
 30% Conditioned medium from 6 month primary fetal 
hepatocyte culture 
 20% Fetal bovine serum 
 
Table 4 Final Culture Conditions For Human Fetal Liver Progenitor Cells




Characterisation of the Human Fetal Liver Stem Cell  
 
 
3.1 Morphology of Fetal Liver Progenitor Cells  
Human fetal liver progenitor cells are small cells at 10um compared to hepatocytes 
which were 60-100um in diameter. They grow in tight clusters forming a heaped up 
3-dimensinal clump of cells rather than a monolayer, a feature of human stem cells. 
They have a large nucleus with scanty cytoplasm exhibiting high nuclear-cytoplasmic 
ratio. Electron microscopy confirmed the scanty cytoplasm and the lack of organelles 
such as mitochondria and endoplasmic reticulum typical of hepatocytes. In addition, 
no bile canaliculi are noted in these cell clusters.  (Figure 3.1) 
 
3.2 Self-regeneration 
To determine cell regeneration, cells were maintained in culture and passaged using 
the technique described. They could be maintained for up to 20 passages for more 
than 6 months. BrdU labeling and Ki67 showed an increase in proliferation rate of 
these cells compared to the hepatoblast or non-parenchymal cells in fetal liver. To 
measure the growth curve of these cells, we used  2,3-bis(2-methoxy-4-nitro-5-
sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide (XTT) assay 
which used calorimetric quantitation of cell metabolism to determine the cell numbers 
in culture. As the progenitor cells were grown on irradiated feeder layers, subtraction 
of activity from the feeder layers was performed by using a control plate with same 
number of feeder layers but no progenitor cells and followed through in parallel. From 
the assay, the doubling time of these cells was estimated to be 46 hours, which is 
typical of  human stem cells.   
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Self regenerative capacity was determined by comparing cells from Passage 0 (source 
cells), Passage 5 and subsequently Passage 10 cells. To determine that regeneration 
resulted in the same cells with subsequent passages, cells were immunophenotyped 
for EPCAM, CD44 and albumin and confirmed that continued culture of these cells 
did not lose their immunophenotype. Similarly, cells from different passages 
maintained the same plasticity which is described later in detail. (Figure 3.2) 
 
3.3 Are progenitor cells clonally derived? 
Using the technique described, each cluster of progenitor cells appeared to arise from 
a single cell. Further isolation was performed with serial dilution to isolate single cells 
on feeder layer cultures. Following the cultures serially, colonies from a single cell 
were obtained and subjected to clonality validation using the Humara assay132 on 
female specimens. This assay capitalizes on the random lyonisation of one of the X 
chromosomes in females. In females with heterozygous Humara X allele, lysing the 
DNA at specific site with HhaI on the unmethylated X chromosome will reveal 2 
different length fragments of the allele with nested RT PCR. A colony of cells, by 
random chance, would express both fragment length. A single cell and its clonal 
progeny would however have only 1 fragment length as the same X chromosome is 
lyonised. We raised 3 progenitor cell colonies from a single heterozygous female 
specimen (no. 18849). Using an inactivation ratio (density ratio of least-intense band 
to more-intense band, before compared with after digestion) of  <0.441, all three 
colonies derived showed nonrandom skewed inactivation of the unmethylated 
Humara X allele, confirming that colonies derived using this technique were likely to 
be clonal in origin. (Figure 3.3) 
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3.4  Determination Of Telomere Length 
To test the self-regenerative extent of these cells, we tested the telomere length of 
colonies from P0,P5 and P10 colonies.  In differentiated human cells, as telomerase is  
inactive, telomere length became progressively shorter with repeated divisions. On the 
other hand, progenitor stem cells express telomerase and are able to maintain the 
telomere length. Southern blot analysis for the telomere length was performed using a 
commercial kit. Colonies of progenitor cells that had been passaged up to 20x and 
maintained over 6 months showed that the telomere length was maintained across 100 
population doublings and the telomere length was comparable to that of a positive 
control stem cell population. (Figure 3.3)  
 
3.4  Stem Cell characteristics 
To explore the stem cell characteristics in these cells, clusters of cells were 
cryopreserved either directly or with commercial scaffold. Sections were then cut and 
immunofluorescence or immunohistochemistry performed, with confirmation by 
either RT-PCR (when confirming negativity) or immunoblotting (when confirming 
positivity). Fetal liver progenitor cells were positive for stem cell markers CD34, Thy-
1, SSEA-4 and c-kit. Oct-4 staining was equivocal and was classified as negative for 
stringency.  These markers are consistent with a stem-cell signature133 and have been 
reported in mouse liver progenitor cells. These cells appear to be committed to 
endodermal lineage and express a variety of epithelial markers including CK18, 
CK19, EPCAM and E-cadherin. Yet surprisingly, they were negative for albumin and 
alphafetoprotein which was contradictory to reported liver stem cell markers known at 
that time.  (Figure 3.4) 
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To determine that these were not non-parenchymal cells, cells were stained for 
CD44h (a mesenchymal marker then), vimentin and anti smooth muscle actin.   
Progenitor cells are strongly positive for CD44 and vimentin but negative for anti-
smooth muscle actin, CD105, CD73, CD31  and Sca-1.   
 
To determine that they were indeed committed liver progenitor cells, we performed 
RT-PCR on HNF 1alpha, 1 beta, 3beta and 4alpha. HNF 1alpha, 3beta and 4alpha  are 
the earliest transcripts in liver cell specification. To our surprise, these transcripts 
were absent in our cells. (Figure 3.5) 
 
3.5 Interpretation 
The isolated fetal liver cells we have isolated are typical of human progenitor cells. 
They are small with high nuclear-cytoplasmic ratio. Like human stem cells, their half 
life is moderate about 46 hours although they regenerate much faster than mature 
hepatocytes. They self-regenerate and are maintained up to 20 passages over 6 
months, in which they undergo more than 100 population doublings with maintenance 
of immunophenotype, morphology, differentiation potential and telomere length. 
They have a stem cell signature that is similar to what has been reported in murine 
liver oval cells. Yet unlike murine oval cells or even the surrounding hepatoblast or 
the more differentiated hepatocytes, they do not appear to have entered liver 
specification yet, testing negative for albumin, AFP and are negative even for the 
earliest transcription factors that specify the liver lineage. Instead, they carry a mixed 
epithelial-mesenchymal marker set that has previously not been described before. The 
human fetal liver progenitor cell isolated thus represents a distinct population of self-
regenerating progenitor cells. (Table 5) 





























One of the main criteria of a stem cell is that it must be able to give rise to at least 2 
different functional cell types through differentiation10. In the liver, the 2 readily 
differentiated specialized cell types are the hepatocyte and bile duct cells. The 
challenge is that while the liver performs many functions, few of these functions are 
exclusive to the liver and to prove successful and meaningful differentiation, one 
would require exhaustive evidence that progeny cells can perform the myriad of 
functions of mature hepatocyte or bile duct cells. 
 
4.1 Hepatocyte Differentiation 
4.1.1 Can liver progenitor cells differentiate into hepatocytes?  
To induce differentiation, progenitor cell clumps were transferred onto  collagen 
plates at low density. Hepatocyte differentiating medium based on William’s E 
medium was used with withdrawal of FGF, conditioned medium and complex fatty 
acids. Dexamethasone 10% as well as oncostatin M50 was then added to cultures. 
Cells migrated into monolayer configuration and became much bigger in size by D3. 
At D8, they took on a polygonal morphology and are indistinguishable from adult 
hepatocytes by D15. Similar to adult hepatocytes in culture, these differentiated cells 
stopped proliferating, became irregularly shaped, developed vacuoles and were lost 
after 3 weeks. This phenomenon is precisely similar to adult hepatocytes and 
underlines the current limitation of being unable to maintain differentiated 
hepatocytes in culture. (Figure 4.1) 
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As fetal liver progenitor cells differentiated to hepatocytes, they started to express 
albumin at D3 and by D21, most of the cells were strongly positive for albumin. At 
the same time, AFP which was negative in progenitor cells, became transiently 
positive at D3-D5 but disappeared as full maturation occurred, recapitulating what 
happens in normal liver development.  These trends were corroborated by 
immunoblotting and RT-PCR (Figure 4.2)  
 
On re-assessing the transcripts that specified for hepatocytic lineage, HNF1beta, 3beta 
and 4alpha, which were not detectable in the progenitor state are now positive and 
indicate cell fate commitment into hepatocytic lineage. (Figure 4.2) 
 
4.1.2 Mesenchymal-Epithelial transition during hepatocytic differentiation 
To determine whether epithelial and mesenchymal markers are co expressed in the 
same cells and what happened to the mesenchymal markers as these progenitor cells 
transit into hepatocytes, we co-labeled albumin and vimentin with different colour 
probes and tracked their expression during D0-D12 of hepatocytic differentiation. As  
reported, progenitor cells were negative for albumin but positive for vimentin. By D3, 
progenitor cells were positive for both albumin and vimentin with co-localisation of 
both antigens in the same cell. Upon further differentiation, vimentin and CD44 were 
down regulated and were lost completely when albumin became fully expressed. This  
phenotypic change is characteristic of mesenchymal–epithelial transition and suggests 
that fetal liver progenitor cells represent transitional cells between mesenchymal and 
endodermal lineages. (Figure 4.3) 
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4.1.3 Functional Analysis of differentiated Hepatocytes.  
We tested progenitor cells, partially differentiated (D6)  and fully differentiated cells 
D21)  extensively for hepatocytic functions.  
 
4.1.3.1 Protein Function 
Hepatocytes are known to express albumin and although many cells may be coaxed 
into turning on the albumin gene expression with promoters, secretion of  albumin 
protein is one of the key functions of mature  hepatocytes. Albumin concentration in 
culture supernatant was assayed using quantitative ELISA and showed a accumulative 
secretion of albumin from 180 ng/ml at D5 and 1.2g/ml at D15. (Figure 4.4) 
  
Differentiated cells also progressively expressed alpha-1 anti-trypsin with 
differentiation. This was demonstrated in both immunofluorescence and 
immunoblotting. (Figure 4.4) 
 
4.1.3.2 Glycogen Storage 
Hepatocytes are able to convert glucose into glycogen stores and this was detectable 
in differentiated hepatocytes using Periodic Acid Schiff (PAS) stain. To confirm the 
specificity of glycogen, the purple colouration is lost after digestion of glycogen by 
diastase. (Figure 4.5) 
 
4.1.3.3  Liver specific cytochrome P450 
Hepatocytes play an important role in drug metabolism and excretion. Most of the 
drug and toxins metabolism is via the cytochrome P450 pathways. While none of the 
P450 enzymes are specific for the liver, the inducibility of these P450 enzymes such 
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as the ubiquitous 3A4 and more specific 2B6 is a specific feature of hepatocytes. 
Instead of demonstrating upregulation of CYP mRNA, we tested the protein 
expression of 3A4 as well as the functional effects of 2B6 on   pentoxyresorufin-O-
depentylase (PROD) before and after induction with phenobarbital to demonstrate 
functional inducibility.  Induction of differentiated cells increased Cytochrome 3A4 
proteins by 1.6 x using semi-quantitative density assay of immunoblot while 
calorimetric PROD assay showed up-regulation of 2B6 activity by 1.4x. (Figure 4.5) 
 
4.1.3.4  Electron microscopy  
While single genes and proteins may be turned on in cells by molecular manipulation, 
only hepatocytes form anatomical bile canaliculus with neighboring cells. These bile 
canaliculus are conduit systems to carry bile and bile salts from the hepatocytes as 
they organize into hepatic cords. With hepatocyte differentiation protocol, electron 
microscopy showed that progenitor cells show an increase in size and reduction of 
nuclear-cytoplasmic ratio due to relative increase in cytoplasm. Endoplasmic 
reticulum, mitochondria and vesicles increase in numbers.  Electron microscopy also 
showed definite characteristic presence of bile canaliculus between neighbouring 
cells, a feature not present in progenitor cells. (Figure 4.6-4.7) 
 
4.1.3.5 Infectibility with Hepatitis B Virus 
Hepatitis B virus has almost exclusive specificity for human hepatocytes and 
infectibility of cells is tantamount to a test of hepatocyte phenotype. To test this 
feature, differentiated hepatocytes were cultured with Hepatitis B virus isolated from 
serum of patients with high titres of chronic hepatitis B. Differentiated hepatocytes 
were washed extensively and supernatant and cells collected over time. New batches 
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of hepatocytes were exposed sequentially to determine durability of infection and true 
viral replication in these cells.  HBsAg using ELISA as well as HBV DNA using 
quantitative RT PCR) was positive up to 16 days in culture. Subsequent new batches 
of hepatocytes exposed to supernatant of these cells showed infection with positivity 
and successive increase in HBsAg and HBV DNA titres. HBc Ag was detectable by 
immunofluorescence in nucleus as well as cytoplasm of infected cells indicating entry 
into nucleus and viral replication within the cytoplasm. To further confirm true 
infection, integration and replication of Hepatitis B virus in the cell, cccDNA, a 
marker of viral integration, was detected in cell lysates of infected cells using RT 
PCR. Electron microscopy also showed corroborative presence of Hepatitis B viral 
particles in endosomes of hepatocytes differentiated from progenitor cells. (Figure 
4.8-4.9) 
 
The potential of having such an in vitro culture system has significant implications in 
studying Hepatitis B virus pathogenesis as well as in development of new drugs for 
Hepatitis B. As demonstration of principle of proof of this potential application,  
differentiated hepatocytes were infected together with antivirals such as lamivudine or 
adefovir. As expected, antivirals blunted HBV DNA production into the supernatant 
in keeping with suppression of Hepatitis B replication. (Figure 4.9) 
 
4.2 Bile Duct Differentiation - Can Fetal liver Progenitor Cells form bile ducts?  
Progenitor/ Stem cells are precursor cells that are able to give rise to at least two 
different specialized cell types in the tissue/organ structure. To prove that the cells 
derived from the fetal liver were indeed liver progenitor cells, in vitro differentiation 
of progenitor cells into biliary cholangiocytes were undertaken. Liver progenitor cells 
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were cultured in bilayered 3D collagen gels to provide polarity signals to these cells. 
Differentiation medium consisted of Williams E, insulin plus dexamethasone, 
conditioned medium from fetal hepatocyte culture 50% and pulse bFGF 40ng/ml. 
Unlike previously reported protocols that did not work in our hands, pulsed basic 
Fibroblast Growth Factor (FGF) was used, adopting the embryological developmental 
principle of providing a FGF gradient for inducing directional branching and tube 
formation.   
 
4.2.1 Morphology 
Progenitor cells in cholangiocyte differentiation culture took on a very different 
morphology. Cords of cells streaked out linearly and reorganized into cystic and 
tubular structures. By D7, the cells were arranged in 2 forms: 3-dimenstional cyst like 
structures were seen while in other areas, branching tubes were seen with canalization 
in the middle. The internal lining of these cyst-like structures became columnar in 
orientation and electron microscopy confirmed the presence of microvilli in the 
luminal pole, a key feature of bile duct cells.  (Figure 4.10-4.11) 
 
4.2.2 Immunophenotype 
Immunostaining with CK19 and CK7, markers of bile duct epithelium, were 
performed on D7 differentiated cells. CK19 are positive in progenitor cells but are lost 
in differentiated hepatocytes. In these cells, they continue to be positive and at the 








4.2.3 Gamma glutamyl transferase. γGT/GGT 
Gamma glumayl transferase is involved in the transfer of amino acids across the 
cellular membrane. It is present in all cells but is particularly concentrated in 
hepatocytes, bile duct cells and kidney. GGT was assayed using Rutenberg‘s 
histochemical staining134 and showed that while human fetal liver progenitor cells 
were weakly positive for GGT, the intensity of GGT was greatly enhanced in the 
branching tubes obtained in bile duct differentiation cultures.  (Figure 4.12) 
 
4.3 Interpretation 
By changing environmental cues, we were able to differentiate progenitor cells into 
two separate progenies of functional hepatocytes and biliary cholangiocytes. These 
differentiated progenies showed consistent morphology, tissue organization as well as 
molecular immunophenotype consistent with their differentiated cell type. In addition, 
we performed extensive functional analysis to confirm that these cells in vitro were 
functional differentiated cells. The human fetal liver progenitor cells have fulfilled the 
2 main criteria for stem cells: Self regeneration and ability to differentiate into at least 
2 functional progeny cells.  
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Exploring the plasticity 
 
Stem cells are highly plastic and have the ability to cross stochastic lineage fate to 
form other cell types.  The putative embryonic stem cells obviously can differentiate 
into any of the dermal lineages. Adult stem cells would seemingly have more of a 
hurdle especially if they are derived from terminally differentiated tissues. However 
several reports have surfaced that mesenchymal cells such as Multipotential Adult 
Progenitor Cells107 or even bone marrow mesenchymal cells101 can be 
transdifferentiated into hepatocytes. It is not surprising since every cell continue to 
hold on to the same 46 chromosomes and complete set of genes, it is conceivable that 
tissue specific stem cells may not have locked down their specification fate. By 
reprogramming the relevant genes through environmental manipulation, it is possible 
to push the cell into other lineages. Fetal liver progenitor cell have seemingly mixed 
endodermal-mesenchymal markers and have yet to undergo liver specification. We 
thus attempted to differentiate these cells into mesenchymal lineages of bone, 
cartilage, fat and endothelial cells.   
 
All differentiation protocols were performed in triplicate with P1–P4 and P8–P12  
progenitor cell colonies. Percoll gradient separation was used to isolate human fetal 
MSCs (34) and parenchymal primary fetal hepatocytes (35) for use as controls. 
Protocols were adapted from publication on mesenchymal transdifferentiation101 and 
successful differentiation were based on at least 2 confirmatory markers with 
mesenchymal stem cells from fetal liver as positive control. (Table 6) 
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5.1 Fat/ Adipocyte Induction 
Fetal liver progenitor cells were transferred onto fibronectin plates and cultured using 
fat differentiation medium containing the key components of 3-isobutyl-1-
methylxanthine,  hydrocortisone,  indomethacin, and horse serum. Cells increase in 
size and by D9, 40% of cells demonstrate accumulation of coalescing vacuoles that 
stain positive for fat (Oil red O). This was in contrast with differentiated hepatocytes 
which do not survive in fat induction medium. Derived fat-like cells also express 
peroxisome proliferator-activated receptor γ2 (PPAR γ2) mRNA which were negative 
in fetal liver progenitor cells and differentiated hepatocytes. (Figure 5.1) 
 
5.2 Bone/Osteogenic Induction  
Cultured in fibronectin plates with DMEM(High glucose), dexamethasone, -glycerol 
phosphate and ascorbic acid,  10% FBS and antibiotics, cells become elongated and 
formed a complex meshwork with irregular processes. By D14, individual cell 
morphology was no longer discernible and instead, large amounts of cellular matrix 
were noted between the cells with areas of deposits which stained positive for calcium 
using von Kossa stain. RNA harvested from these cells also express strong 
osteopontin mRNA. Osteopontin mRNA was absent in differentiated hepatocyte 
although it was weakly positive in progenitor cells as had been previously reported46.  
(Figure 5.2)  
 
5.3 Cartilage/ Chondrogenic  Induction  
The principle of cartilage induction hinged on creation of mass of cells in suspension. 
The cells in the middle of the mass would be in relative hypoxic conditions and 
stimulated by  proline, transforming growth factor-β3 and ITS (insulin-transferrin-
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selenium), would be induced to become cartilage cells expressing proteoglycans as 
well as cartilage specific type II collagen. 3 weeks of culture in polypropylene tube 
was needed for cells to organize in a ringed sphere. Extracellular matrix in the core 
was positive for glycosaminoglycans, which stains pinkish red with Safranin and is 
positive for cartilage-specific collagen II using immunofluorescence.  The negative 
control differentiated hepatocytes do not survive in cartilage differentiating medium 
(Figure 5.3) 
 
5.4 Endothelium Induction  
Cultured on fibronectin plates with endothelium induction medium containing 
platelet-derived growth factor (PDGF)-CC135, fetal liver progenitor cells became 
spindle-shaped with formation of linear channels between cells. After 9 days of 
induction, 38% of cells are positive for von Willebrand factor (immunofluorescence) 
and 28% of cells express CD31. Both of these factors are specific for endothelium and 
are not found in both progenitor cells and differentiated hepatocytes.  (Figure 5.4) 
 
5.5 Ectodermal differentiation 
Ectodermal differentiation was attempted using published protocols from MAPCs107. 
However, despite repeated attempts, fetal liver progenitor cells do not survive in 
cultures beyond 3-4 days and neuronal transdifferentiation was unsuccessful. 
 
5.6 Interpretation:  
Human fetal liver progenitor cells can clearly behave like mesenchymal stem cells 
and, with appropriate stimulation, give rise to each of the mesenchymal lineage-like 
cells. It is important to note that positivity of 2 markers does not define a cell type and 
  Page 64  
 
 
in many aspects, the transdifferentiated cells have not undergone detailed functional 
analysis of mesenchymal lineages. However, it does appear fetal liver progenitor cells 
is fairly plastic and are relatively easy to differentiate into mesenchymal lineages-like 
cells. Ectodermal lineage transdifferentiation however appears much more difficult. 
Whether this is due to technical limitation or physiologically, the threshold for 
ectodermal transdifferentiation is much higher is not known. What can be concluded 
is that fetal liver progenitor cells demonstrate multipotency and plasticity in that they 
can differentiate into at least 2 dermal lineages with appropriate stimuli.  
  




















Table 6. Protocols for Mesenchymal Lineage Transition 
 
Bone Cartilage Fat Endothelial Nerve 
DMEM-LG DMEM HG DMEM-HG DMEM-HG DMEM-HG 








 ITS+ Insulin   
Vit C Vit K Indomethacin   
dexa Dexa dexa   
 TGFB3  PDGF CC  




Demonstrating In vivo Transplantatability  
 
6.1 In vivo Function 
The key test of practical usefulness of a progenitor/ stem cells lies in demonstrating 
ability to undergo in-vivo repopulation, perform repair and regenerative functions and 
if possible, show survival benefit. Can fetal liver progenitor/ stem cell be transplanted 
into animal models where it can survive, engraft, integrate into target tissue, 
differentiate and function like normal differentiated cell? A pilot study was 
undertaken to establish the optimal conditions for transplantation. (Table 7) 
 
To achieve repopulation of human cells in xenotransplant models, 4 critical issues 
were studied: 
1) Immunopermissive animals models 
2) Ability to deliver cells to target organ 
3) Regenerative stimulus for cells to grow 
4) Competitive advantage for progenitor cells to grow 
 
6.1.1 Immunopermissive model 
6.1.1.1 Nude Mice model  
Nude mice with deleted B cells and T cells were first used in transplantation 
experiment. 1 million human progenitor cells were injected intrasplenically after 
treatment with Fas ligand136. Liver injury and growth stimulus was induced using 2/3 
partial hepatectomy model. Mouse serum was examined for human specific albumin 
at D12 and at D28 when mice were sacrificed. Immunohistochemistry and H&E 
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stains were then performed looking for human specific albumin staining cells in liver 
and spleen. Human specific albumin was negative in mouse serum at both time points. 
On H&E histology, clusters of abnormal looking dead cells were seen strewn 
randomly throughout the mouse liver but no positive human albumin staining was 
noted. These clusters were surrounded by fibrous strands and mononuclear cells and 
were presumed to be due to imunnological rejection mediated by Natural Killer(NK) 
cells. (Figure 6.1) 
 
6.1.1.2 Rag2 double knockout mice  
An alternative model of (C57BL_6J _ C57BL_10SgSnAi)-[KO]gc-[KO]Rag2 which 
ware lacking T,B and NK cells and specially bred for transplantation purposes were 
then used for repopulation studies and were found to be more tolerant of 
xenotransplantation137.  (see details below)  
 
6.1.2 Ability to deliver cells to target organ 
Hepatocyte transplantation has been performed via intra-portal route or intrasplenic 
route. The intrasplenic route is technically easier and has been shown that almost all 
cells will migrate over to the liver by 24 hours138. As the portal vein network traverses 
through the liver cords via the portal tract, transplanted cells enter the hepatic 
parenchyma by squeezing out from within the endothelial sinusoidal space. Reported 
success rates published to date have suggested 1-2% repopulation. We thus surmised 
that the low degree of repopulation is due partly to cells traversing through the hepatic 
system without homing and instead, getting stuck embolically in organs such as the 
lung.  To increase the yield of transplanted cells entering the hepatic cords, we treated 
the mouse with modified ischemic-reperfusion conditioning just prior to 
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transplantation. Ischemia-reperfusion is known to injure the endothelial cells lining 
the sinusoids139, opening up gaps for enhanced passage of progenitor cells.  
 
In a pilot trial, 2 Rag-2 mice were treated with ischemic-reperfusion prior to 
transplantation with 2 mice as controls. Live surgery was performed and the pedicle 
of median and left anterolateral segments were dissected, exposed and clamped with 
vascular clip for 20 min and released for reperfusion of 10 min before progenitor cells 
were injected into the spleen. After 14 days, the left lobe of the liver was then 
assessed for human cells using anti-human albumin by immunofluorescence/ 
immunohistochemistry.  The animals with ischemia reperfusion showed 12-16% 
increase in number of human cells on mouse histology using identification with 
human specific albumin.  
 
6.1.3 Regenerative stimulus for cells to grow 
Growth stimulus was provided to the progenitor cells by injury induction to the native 
liver after transplantation of human fetal liver cells. Comparison was made between 
classical two third partial hepatectomy and intraperitoneal injection of carbon 
tetrachloride. In partial hepatectomy, 70% of liver mass i.e.  the median and left 
lateral lobes are removed while in carbon tetrachloride, injection was given 
intraperitoneally for 3 weeks in 2 mice each140. Repopulation of human progenitor 
cells in mouse was not significantly different between the two techniques. Decision 
was made to use the carbon tetrachloride model as it simulated a real life chemical 
injury model and the advantage in repopulation from ischemia reperfusion is not lost 
when the median lobe and left lobe are removed during the 2/3 partial hepatectomy.  
Carbon tetrachloride also had the advantage that injury is usually at zone 3 of the 
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hepatocyte lobules, transplanted cells at zone 1 will be spared from direct toxicity yet 
receive a strong regenerative stimulus. 
   
6.1.4 Competitive advantage for progenitor cells to grow 
To give competitive advantage to our cells, we treated mice with 2 intraperitoneal 
injections of retrorsine 2 weeks apart to block replication of native hepatocytes140. 
This would theoretically block the natural repair and regenerative pathways in injured 
liver, giving a chance for the transplanted cells to proliferate to repair the liver. Pilot 
dose titration experiment was carried out initially with 6 Rag -/- mice with each  mice 
at different doses of retrorsine ranging from 50-80 mg/kg at 10mg increments. Mice 
that received 70 ug and 80ug/kg dose died and 60ug/kg was determined to be the 
optimal dose for inhibition of native hepatocyte replication.  
 
6.2 Transplantation 
A total of 38 male Rag-/- double knockout mice at 6 weeks were treated with 2 doses 
of intraperitoneal retrorsine 2 weeks apart.  Transplanted mice were administered with 
4 million human fetal liver progenitor cells enriched in primary fetal liver cultures via 
the intrasplenic route after ischemia-reperfusion. Control animals were given sham 
surgery but infused with equivalent 0.2 mls phosphate buffered saline intrasplenically. 
One week after transplantation, animals were injected with weekly doses of carbon 
tetrachloride weekly for 3 weeks. Mice were then sacrificed at week 4 to determine if 
human progenitor cells persisted and followed up at week 12, 24 and 36 to track the 
repopulation levels. A total of 10 mice died before their designated timepoints. These 
were due to deaths post retrorsine (5 mice), post transplantation due to technical 
complications such as splenic laceration or uncontrolled bleeding.    (Figure 6.2) 




6.3  Localising the engrafted  human cells 
6.3.1 Haematoxylin and eosin staining 
H&E staining showed the preservation of normal liver architecture in all mice and 
degree of injury and fibrosis in both transplanted and control mice were not easily 
discernible. At high magnification of mouse liver sections which had received 
transplants, clusters of dead cells could be seen stuck in portal veins. In addition, there 
were sporadic clusters of larger and more eosinophilic cells around the portal veins 
tributary where the cells had been introduced into the liver in association with 
hemorrhagic areas. (Figure 6.3)  
 
6.3.2 Human specific albumin to identify human hepatocytes  
Serial sections showing the presence of human cell clusters were stained with human 
specific albumin antibodies using immunofluorescence label. Using serial sections for 
localisation, the same large cells seen in H&E slides were confirmed to express 
human specific albumin. With immunohistochemistry, these cells become even more 
easily distinguishable with larger nucleus, cytoplasm and irregular shape. Other than 
the occasional cell clusters with >100 cells, isolated sprinkling of human specific 
albumin labeling cells can be seen around portal vein tributary. Using image analyzer 
and random counting of 10 high powered field, the degree of repopulation was 
estimated to be 0.8–1.7% in these mice. (Figure 6.3-6.4) 
 
This was further corroborated by presence of human specific albumin mRNA  in the 
transplanted mice while no human specific albumin staining cells, human albumin in 
the serum or human albumin mRNA were detectable by RT_PCR from the liver 
  Page 75  
 
 
lysate of control mice. These data indicate that human fetal liver progenitor cells that 
were intrinsically albumin negative, can survive and differentiate into functioning 
hepatocytes in an in vivo injury model.  (Figure 6.4)  
 
6.3.4 Confirmation of co-labeling with human hepatocyte-paraffin antigen 
To further confirm that these were indeed human cells, a second human specific 
marker (human –specific Hep-Par) was used to stain these cells and showed that the 
same cells that were human albumin positive, also stained positive for human Hep-Par 
by co-labeling experiments. (Figure 6.4)  
 
6.3.5 Identifying Human Chromosomes As Ultimate Proof Of Human Origin 
Brulport et al141  had reported that in vivo transdifferentiation results must be 
interpreted in caution as besides transdifferentiation, lateral gene transfer of human 
genes into mouse liver due to phagocytosis of dead human cells or through fusion 
with mouse hepatocytes may result in  identification of human genes or product in 
mouse cells. To exclude lateral gene transfer, in situ hybridization was performed 
with human centromere probe which picked up only human chromosomes. Cells that 
stained positive for human specific albumin and hep-Par did stain positive for human 
specific centromere.  (Figure 6.5) 
 
6.4 Excluding Fusion in human derived cells in mouse liver 
To exclude the possibility of fusion, we combined in situ hybridization with human –
specific centromere probe labeled with alexa 488 green and mouse centromere probe 
labeled with alexa 594. If fusion events had occurred, we would be able to see cells 
that had both human and mouse chromosome and would thus have red and green 
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labels within the same nucleus. In all the 100 nucleus that were analysed, human and 
mice chromosomes were exclusive and there was not a single nucleus that had both 
human and mice centromere together within the same nucleus. Although this does not 
exclude fusion completely, fusion does not appear to be the predominant mechanism 
by which human progenitor cells repopulate the injured mouse liver. (Figure 6.5) 
 
6.5 Functions of in-vivo human cells  
The aim of transplantation lies in the hope that transplanted cells can take over the 
functions of the injured liver and support the injured animal. It is thus imperative to 
establish principle of proof that differentiated cells from the transplanted fetal liver 
progenitor cells are functional and can integrate into the host tissue organ. 
 
6.5.1 Production of albumin into serum 
Albumin production into the serum is a core function of hepatocytes and plays the 
role of carrier proteins for both nutrients and toxins as well as maintenance of oncotic 
pressure. Using the same human specific albumin antibody for ELISA, we were able 
to detect human specific albumin in the serum of transplanted mice. In control mice, 
none of the albumin in serum was of human origin.  (Figure 6.4) 
   
6.5.2 Production and Storage of glycogen  
Periodic Acid Schiff stain was performed to demonstrate functional production of 
glycogen in human derived cells. Human hepatocytes stain more darkly compared to 
the mouse hepatocyte for glycogen. Localising human hepatocytes with human 
specific albumin IHC, serial sections were tested for glycogen and showed that the 
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same large cells staining positive for human albumin were strongly positive for 
glycogen similar to adult hepatocytes controls.  (Figure 6.6) 
 
6.5.3 Integration with native mouse hepatocytes 
Functional hepatocytes integrate with neighboring cells by forming tight junctions at 
canaliculus which can be delineated with ZO-1, a tight junction protein. Co-labeling 
study was performed using human specific Alexa 594(red) antibodies and non 
specific ZO-1 antibody labeled with Alexa 488 (green). (mouse specific ZO-1 
antibodies were not available).   Composite pictures showed that there were cells 
showing human specific ZO-1 localising adjacent to cells expressing mouse ZO-1 
suggesting the formation of shared tight junctions between hepatocytes of human and 
mouse origin. (Figure 6.7) 
 
6.6 How long can human derived cells survive in vivo? 
To test the durability of these cells and whether they continue to expand in vivo as 
well as explore the safety issue from oncogenic point of view,  mice were transplanted 
using the same protocol and followed up in cohorts up to 3 months, 6 months and 9 
months. Repopulation was quantitated by human specific albumin producing cells. 
Repopulation was patchy but repopulation indices and both human specific serum 
albumin concentration and mRNA RTPCR quantification showed a peak at 3 months 
in all animals. This was corroborated by presence of Ki67 positivity in human clusters 
up to 3 months. 1 mice continued to show robust human cells engraftment with large 
clusters of human cells seen on histology, high albumin mRNA on RT PCR and high 
serum human albumin. (Figure 6.8) The persistence of engraftment was noted to 
depend on whether fibrosis persisted in the animals. Animals with continued fibrosis 
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saw robust proliferation of clusters of human cells while animals with escape and 
reversal of fibrosis resulted in loss of human cell clusters, likely due to loss of growth 
stimulus.  
 
6.7  Do fetal liver progenitor cells differentiate into bile duct cells in vivo? 
As carbon tetrachloride injury model is predominantly a hepatocyte injury model, bile 
duct regeneration is not a significant reponse. Using Fluorescent insitu hybridization 
for human centromere probe, occasional human chromosomes within bile ductules 
was noted, suggesting that fetal liver progenitor cells were able to differentiate into 
biliary cholangiocyte in vivo. (Figure 6.9) 
 
6.8 Testing oncogenic potential of  human liver progenitor cell 
Oncogenicity remains one of the hurdles towards use of progenitor cells in clinical 
treatment. To test if transplanted human progenitor cells may undergo transformation, 
clusters of human hepatocytes derived from 9 month samples post transplantation 
were analysed for oncogenic potential. Haematoxylin and eosin sections were 
analysed by 2 senior gastrointestinal pathologists and staining were performed for 
alphafetoprotein, Ki67 and CD34. While cellular disarray were noted, there were no 
evidence of irregular mitosis, dyskaryosis and AFP, KI67 and abnormal patterns of 
CD34 were all negative. To prove that that there were no nuclear aneuploidy, in situ 
hybridization was performed with chromosome 7 and 17 centromere probe, the  two 
commonest chromosome implicated in HCC aneuploidy142. In all the nucleus 
examined, no abnormal numbers of chromosome 7 and 17 were detected. We 
concluded that at least up to 9 months post-transplant, there was no evidence of 
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oncogenic change or aneuploidy in transplanted human fetal liver progenitor cells. 
(Figure 6.10)  
 
6.9 Interpretation 
An immunologically permissive model with ischemia-reperfusion conditioning to 
increase delivery of cells to the injured organ, continued regenerative stimulus and 
competitive advantage are key factors that affect repopulation. Rag 2 KO mice were 
used for these experiments as they were bred especially for human cell transplants and 
were supposedly more immunologically permissible and hardier than NOD/SCID 
mice. Human fetal liver progenitor cells are able to repopulate livers of murine model 
of liver injury. They survive and differentiate into functional liver cells, integrating 
with mouse hepatocytes as well as into the biliary tree. They express albumin, Hep-
par, store glycogen and persist up to 9 months if there is continued regenerative 
stimulus with no evidence of fusion. Human fetal liver progenitor cells do not appear 
to form tumours with nuclear aneuploidy up to 9 months post transplant. 
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Table 7 Pilot Trial of optimal conditions for in vivo transplantation  
  
Animal Model  # of mice Repopulation  
Nude Mice 2 transplanted: 1 control  0% 
Rag γc double KO  2 transplanted: 1 control  0.93- 1.14%  
      
Delivery of Cells     
Intra-portal  1 0.87% 
Intra-splenic 1 0.922% 
Ischemia- reperfusion + 
Intra- splenic  
1 1.14% 
      
Regenerative Stimulus      
Partial Hepatectomy 1 0.98% 
Carbon Tetrachloride 1 0.91% 
      
Retrorsine preconditioning   % died within 2D 
60ug/kg intraperitoneal 2 0% 
70 ug/kg intraperitoneal 2 50% 
80ug/kg intraperitoneal 2 100% 






Human fetal liver progenitor cells holds tremendous promise in that they represent a 
entity that will allow us to understand normal precursor-progeny development of 
hepatocytes and biliary cells.  
 
They appear to be a distinct population in human fetal liver and can be enriched and 
isolated using a novel technique that capitalized on unique characteristics of their 
resistance to geneticin and requirement for feeder layers. Interestingly, they have 
mixed mesenchymal-epithelial properties and show multipotency in being able to 
differentiate into progenies of both these lineages.  
 
7.1 Where do fetal progenitor cells come from?  
The fetal liver contains a plethora of cells at mid-trimester. It is the nesting ground of 
hematopoietic stem cells, mesenchymal stromal cells, hepatoblast, maturing 
hepatocytes, biliary cholangiocytes as well as liver non-parenchymal cells such as 
Kupffer cells, myofibroblast and endothelial cells. Prospective origins of our fetal 
liver progenitor cells would include 
1. Dedifferentiated cell from hepatoblast/hepatocytes  
2. Hematopoietic stem cell origin 
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7.1.1 Human fetal liver progenitor cells are not dedifferentiated hepatocytes 
To prove that the progenitor cells are a natural entity within the fetal liver and not a 
culture artifact due to dedifferentiation of mature hepatocytes in culture, 
immunohistochemistry was performed on fresh fetal liver across various gestations 
staining for EPCAM and CD44.  Cells of similar phenotype were seen at the ductal 
plates in liver specimens of less than 14/52 gestation. By about 16 weeks, these cells 
start radiating out from portal tracts, suggesting that these cells exist de novo in fetal 
livers. 
 
To exclude the possibility of hepatocytes dedifferentiating into progenitor cells, we 
performed lineage tracing by tagging the hepatocytes in primary fetal liver culture. 
Percoll density fractionation was used to isolate hepatocyte subfraction which was  
determined to be 89% pure using immunofluorescence with human albumin.  These 
cells were transfected with GFP-labeled lentiviral vectors driven by the EF1alpha 
promoter 143-144. Transfection efficiency was almost 90%. Primary hepatic cultures 
were then reconstituted by adding labeled hepatocytes with unlabelled non-
parenchymal fraction from the same specimen into coculture. The same enrichment 
protocol was used and progenitor cells isolated using the same technique described. 
Progenitor cells colonies were then checked to see if they were GFP producing. GFP 
positivity would imply that they were derived from GFP labeled hepatocytes that had 
dedifferentiated in cultures. In all 10 colonies studied, none of them were GFP 
expressing making it unlikely by chance, for progenitor cells to be derived from 
dedifferentiating hepatocytes.  (Figure 7.1)  
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7.1.2 Human fetal liver progenitor cells are not hematopoietic stem cells derived. 
Human progenitor cells can be identified on fetal liver histology and was noted in 
ductal plates and portal tracts. These were anatomically separate from hematopoietic 
stem cells seen in vascular sinusoids making them unlikely to be of hematopoietic 
origin. CD45 and Sca-1 antibody staining (markers for hematopoietic origin)145 were 
performed and progenitor cells were uniformly CD45 and Sca-1  negative.  
 
7.1.3 Human fetal liver progenitor cells are not mesenchymal stem cell derived 
Using a similar lineage tracing technique, we isolated mesenchymal stem cell fraction 
using Percoll. Purity was 85% using Cd44 immunofluorescence count and 
mesenchymal stem cells were transfected with GFP lentivirus up to 90% efficiency. 
Similar constitution was performed with unsorted culture from the same specimen. Of 
8 colonies isolated using the same technique described, none of the progenitor cell 
colonies were positive for GFP. (Figure 7.2) These progenitor cells were also negative 
for mesenchymal markers such as CD73, CD105 and CD31145. Taken together, it is 
thus very unlikely that fetal liver progenitor cells had arisen from mesenchymal stem 
cells.   
  
7.2 A meso-endodermal cell that undergoes epithelial mesenchymal transition 
Human fetal liver progenitor cells co-express epithelial and mesenchymal markers 
and are able to transit between the two lineages, differentiating into liver cells and 
mesenchymal lineages.   Could the mixed epithelial and mesenchymal phenotype and 
multipotency in differentiation been due to impure culture of both epithelial 
progenitor cells and mesenchymal support cells?  Co-localisation studies have shown 
that the same cell co-expresses both epithelial and mesenchymal features 
  Page 92  
 
 
simultaneously. (Figure 4.3) Differentiation experiments had been performed from 
colonies that were clonally derived and clonality of colonies derived using the method 
had been validated with Humara assay, In addition, cultures were propagated in 
multiple passages and observed under microscope to be uniform, homogenous and of 
high quality in morphology before being subjected to differentiation protocol. NIH 
3T3 feeder cells have been irradiated or mitomycin treated and in repeated cultures 
that numbers in hundreds of combined passages, escape with overgrowth of NIH3T3 
has never been observed. In addition, all these observations and experiments 
including dual lineage immunophenotype and potency in differentiation have been 
successfully replicated and reported subsequently in 2008 by other researchers43-44, 146, 
corroborating our data.  
 
Human hepatocytes have been traditionally thought to be endodermally derived. Yet 
elsewhere in the animal kingdom, 80% of the turtle liver is apparently derived from 
the mesenchyme147. Additionally, multiple studies have shown that MSCs or 
mesoderm-related multipotent adult progenitor cells in both mice and humans can 
differentiate into hepatocytes101, 107. Mesenchymal–epithelial transitional cells are not 
uncommon in fetal development148 and have been demonstrated in both rodent 
neonatal149 and fetal livers150, as well as human fetal livers, in which they have been 
reported to support hematopoiesis127. It has been hypothesized that mesoderm and 
endoderm arise from a common bipotential mesendoderm precursor151. Tremblay and 
Zaret152 demonstrated that cells from the ventral midline of the endoderm lip, 
probably originating from the mesendodermal prechordal plate, give rise to part of the 
liver bud. Human Fetal liver progenitor cells appear to have mesendodermal origin, 
but further fate-map analysis and characterisation of liver specification profiles will 
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determine whether they arise from the cells described by Tremblay and Zaret152 or are 
from a distinct progenitor niche.  We thus propose that human fetal liver progenitor 
cells are mesenchymal–epithelial transitional cells and suggest that they have a 
mesendodermal origin.  
 
7.3 What happens to these cells in adult liver 
Schmelzer et al43-44 has subsequently reported similar cells that they have isolated 
from both fetal and adult liver. These cells have the same immunophenotype and 
appear to be the progenitor cells that reside in the canals of Hering in adult liver. This 
would suggest that this population of progenitor cells exist from fetal liver and are 
maintained through adult life as a quiescent niche, to be activated only when there is 
significant injury to the liver to help repair and regenerate the liver.  
 
7.4 Future Directions 
7.4.1 A critical analysis of obstacles to use of stem cells in therapeutic 
applications 
Significant challenges still exist before stem cells can be translated into clinical 
applications to treat patients. These challenges include the following: 
 
7.4.1.1 Continual sufficient supply of hepatocytes either from progenitor cells or 
transdifferentiated from multipotent cells. 
Human derived cells are needed in large numbers for purposes of transplant. It is 
projected that a normal sized adult will require at least 200 million cells to have a 
practical sizeable functional benefit. Though stem cells are self replicative, they need 
to be scaled up significantly in short period of time.  
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7.4.1.2 Understanding of regulatory mechanisms that control lineage 
transdifferentiation and hepatocyte specification. 
The key regulatory genes that specify mesenchymal to epithelial transition have not 
been identified. The sonic hedgehog pathway, βcatenin, c-met and E-cadherin 
pathways153,11 have all been reported to be involved in stem cell homeostasis, 
maintenance and differentiation.  Understanding the role of these markers may yield 
targets to further augment the differentiation pathway so as to increase the efficiency 
of hepatocyte differentiation. 
 
7.4.1.3 Meaningful and practically useful physiological function from ex vivo 
hepatocytes for the purpose intended. 
Current assessment of hepatocyte function such as albumin, indocyanine green, urea 
synthesis and cytochrome P450 have been mostly qualitative. Many of the hepatocytic 
functions are also not specific to the liver154. For cellular transplants for liver failure, 
cells will need to demonstrate adequate clotting factors secretion and ammonia 
metabolism. For drug testing, cytochrome P450 functional assays and drug 
metabolism and clearance capacity will need to be  established.  
 
7.4.1.5 Efficacy in survival outcomes in transplantation or dialysis.  
Repopulation is the surrogate marker of in vivo engraftment for most animal studies. 
While these show principle of proof success, demonstration of therapeutic efficacy 
such as improvement in survival or liver function parameters such as bilirubin, 
prothrombin time and ammonia are needed154. Large animal studies of cellular 
transplant or artificial assisted liver devices are also lacking due to the deficiencies in 
animal models of liver injury that closely reflect the clinical diseases seen in patients. 




7.4.1.6 Safety from avoidance of animal products contact (GMP grade) as well as no 
increased risk of oncogenesis. 
Most ES cell lines were reported to be contaminated with animal peptides when 
grown on feeder layers. To move cells nearer to clinical application, Good Medical 
Practice (GMP) protocols need to be developed to avoid contamination. Careful 
testing of cytogenetics of derived cells will need to be done to screen for oncogenic 
potential as well as long term study of transplantation of progenitor cells are needed.  
 
7.4.1.7 Ability to cryopreserve these cells with high viability for use when needed 
For therapeutic applications such as transplants to be useful, the ability to 
cryopreserve large number of cells so that they can be effectively used when needed 
has to be demonstrated. While hematopoietic cells and murine fetal hepatocytes have 
shown resilience during cryopreservation, human hepatocytes have shown significant 
deterioration during cryopreservation and large scale storage remains a challenge. 
Vitrification of ES cells has been shown to be a superior method of cryopreservation 
but large scale vitrification of human hepatocyte colonies for the purpose of transplant 
has not been studied.155  
 
7.4.1.8 No rejection of engrafted cells. 
In the clinical setting, while it will be ideal to grow one’s own autologous cells, the 
pace of acute liver failure will likely necessitate the use of banked similar blood group 
cells. Rejection continues to pose a challenge to the feasibility of cellular transplant.  
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To attain the goal of using these cells for therapeutic applications, the following future 
directions are being pursued: 
 
7.4.2 Optimising cultures to avoid feeder layers and animal products 
For the purpose of transplantation, cells need to be free from animal products to avoid 
risks of zoonosis. Our current culture protocols uses NIH 3T3 feeder cells which are 
mouse embryonic fibroblasts as well as several culture products that are animal 
derived. We have replaced collagen, laminin and FGF with human recombinant 
versions and also replaced bovine serum with human serum with no observable 
deleterious effect on culture of these cells.  
 
To overcome the need for feeder layers, progenitor cells were isolated using magnetic 
flow sorting using EPCAM antibodies conjugated with magnetic beads. Two rounds 
of magnetic sort yields 95% pure population of progenitor cells that are identical to 
the cells we have described. These cells are cultured on laminin at high density in 
transwell membrane or special silicon nitride membranes (in collaboration with Prof 
Hanry Yu) using human fetal liver fibroblasts as feeder layers. Preliminary results 
have shown successful maintenance of these cells using a combination of collagen, 
laminin as well as hyaluronic acid. Cell-cell contact appears to be critical for 
maintenance of these cells.  
 
7.4.3 Study on genetic determinants of stem cell regulation and differentiation 
Preliminary results with collaborators have implicated the role of sonic hedgehog 
pathways in the signaling of stem cell maintenance as well as differentiation and 
epithelial mesenchymal transition34.  Microarray analysis will be performed on 
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progenitor cells as well as differentiated cells to look for unique genetic signatures 
that would identify new surface markers to isolate these cells as well as unravel genes 
involved in stem cell regulation and differentiation. 
 
7.4.4 Establishment of therapeutic effect  
To document principle of proof of fetal progenitor cells in being able to have a 
therapeutic effect, experiments are currently underway using DDC diet and 
galactosamine to create acute and chronic liver failure models of irreversible 
progressive liver injury.  Progenitor cells will be transplanted to determine their 
potential to reverse the effects.  
 
7.4.5 Serial Transplantation of Human Progenitor cells. 
The ultimate proof for a cell to be considered a stem cell is their ability for single cell 
serial transplantation in animal models. This has been achieved for bone marrow 
hematopoietic stem cell. The true stem cell will have to be clonally derived under 
time-lapse microscope tracing. Clonal colonies will need to be marked with lentivirus 
before transplantation into animal model of liver injury. They will then need to be re-
harvested, isolated and retransplanted into another animal to give rise to all lineages 
of the liver to fulfil this criteria of a stem cell.   
 
7.4.5 Risks of Malignancy 
The more pluripotent a stem cell is, the higher the risk of malignancy. Just as 
embryonic stem cells or induced pluripotent stem cells harbour the highest risk of 
teratoma, fetal stem cells being highly plastic, will always need to pass the most 
stringest tests on theirs risks of malignancy before human trials can be attempted.  
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Cells will need to be transplanted in the subcutaneous tissue of SCID mice and 
followed up long term for up to 1 year to document their risks of malignancy. Similar 
cytogenetics testing will need to be donew on long term cultures of these cells.  
 
7.5 Conclusion:  
We have isolated clonal human fetal liver progenitor cells that are capable of giving 
rise to lineages of the adult liver. Systematically characterizing their phenotype and 
ideal niche culture environment, we were able to capitalise on their relative resistance 
to geneticin and isolate them using a novel chemical-mechanical technique. High 
density feeder layers, laminin matrix signaling and fibroblast growth factors are 
needed to maintain their ‘stem cell” state and to keep them proliferating. These cells 
behave more like human stem cells rather than mouse progenitor cells.  Human fetal 
liver progenitor cells appear to have durable proliferative capability and can be 
maintained in culture long term with preservation of telomere lengths. They 
demonstrate multipotent differentiation potential and can be induced to differentiate 
into functional hepatocytes and biliary duct cells in vitro, even after being kept in 
culture for 6 months.  Differentiated hepatocytes can secrete albumin into supernatant, 
store glycogen, metabolise drugs through inducible cytochrome P450 enzymes and be 
infected with Hepatitis B viruses. They can undergo epithelial-mesenchymal 
transition and be differentiated into mesenchymal cell lineages including cartilage, 
bone, adipocytes and endothelial cells. Transplanted directly into injured livers of 
immuno-permissive murine models and given a competitive advantage and growth 
stimulus, they can differentiate into hepatocytes and bile duct cells. These 
differentiated hepatocytes survive up to 9 months post transplant. They integrate with 
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native mouse liver and are functional, expressing human proteins with no evidence of 
transformation. 
 
The successful isolation of these cells has tremendous implications. The ability to 
infect these cells with Hepatitis B infection would provide valuable in-vitro models 
for studying Hepatitis B infection as well as development of new drugs against 
Hepatitis B. More importantly, fetal liver progenitor cells provide natural 
unadulterated cell model to understanding the critical factors and mechanisms that 
determine their stemness, proliferation as well as differentiation and lineage 
transition. This knowledge can be then applied to other stem cell source in our 
attempts to derive large numbers of functional hepatocytes. This will move us nearer 
to the eventual goal of developing progenitor/ stem cell therapies for patients with 
liver failure.  
 
 






   










Detailed Materials and Methods 
 
 
8.1 Cell Culture  
8.1.1 Source and isolation of human fetal liver progenitor cells 
Human fetal livers were obtained from the Central laboratory for Human Embryology 
at the University of Washington as well as Dept of Obstetrics and Gynecology at 
National University Hospital in accordance with protocol approved by the 
institutional review board of both Universities. Primary fetal hepatocyte cultures were 
raised and kept in culture using the Fetal Hepatocyte medium (CSHFM) as previously 
described.50  Cultures were maintained for at least three months to allow enrichment 
of small blast cells before they were passaged with 1mg/ml collagenase(Boehringer 
Ingelheim, Ingelheim,Germany) and 10U/ml dispase (BD Biosciences, Bedford, MA).  
50ng/ml geneticin (Gibco/Invitrogen, Carlsbad, Ca) was added to the P1 culture 
media immediately after passage for 6 days. Colonies of progenitor cells were then 
mechanically isolated under microscopic visual guidance and transferred onto feeder 
culture plates.  
 
8..1.2 Determining ideal Culture Conditions 
To test the ideal conditions for fetal progenitor cultures, three elements including 
culture medium, extracellular matrix substrate as well as feeder layers were studied. 
Plates were coated with laminin (5ug/ml), collagen (1:5), fibronectin (5ug/ml), gelatin 
(5ug/ml) and hyaluronic acid (Suplasyn, Bioniche Life Sciences Inc., London, 
Ontario, Canada), washed and air-dried before use.    
 
8.1.3 Culture and cloning 
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Fetal liver progenitor cells  were cultured on irradiated NIH 3T3 feeder layers (180 
000 cells/ml) coated on collagen(Vitrogen; Collagen Corp., Fremont, CA) /Laminin 
(Invitrogen, Carlsbard, CA) substrate and maintained with 50% CSHFM minus 
dexamethasone, 20% FBS and 30% conditioned medium which was the medium 
supernatant used for primary hepatocyte culture. This was further supplemented with 
bFGF (10 ng/ml) and complex fatty acids (5 mls/l) (both from Sigma Aldrich, St. 
Louis, MO). Medium was changed daily and cultures maintained in incubator at 37’C 
at 6% CO2. Cloning was performed with dissociation by collagenase 1mg/ml and 
serial dilution. Daughter colonies were derived from single or at most 2 cell clusters 
on feeder layers as witnessed under inverse microscope. Colonies were then passaged 
every 10 days using a cut and paste technique similar to that used in human ES cell 
cultures protocols.156  
 
8.1.4   In Vitro Differentiation Protocol 
All differentiation protocols were performed in triplicate with P1-P4 and P8-P12  
progenitor  colonies. Percoll gradient separation was used to isolate human fetal 
mesenchymal stem cells157 and parenchymal primary fetal hepatocytes158 for use as 
comparison controls. Basic culture medium was purchased from Gibco/Invitrogen 
(Carlsbard, CA) and supplements were from Sigma Aldrich (St Louis, MO) unless 
otherwise specified. 
  
8.1.5   Hepatocyte Differentiation 
Cells were plated onto collagen coated plates  at density of 1X104 per cm2. Cultures 
were treated with standard hepatocyte culture medium CSHFM. Oncostatin  M 
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(OSM) (10 ng/mL; R&D Systems, Minneapolis, MN) was added from D3 to further 
augment liver specific markers 
 
8.1.6  Bile duct Differentiation 
Cells were cultured in bilayer 3D fibrillar collagen gel as described.159 Collagen was 
prepared using 8 parts collagen:1 part 1M NaOH and 1part 10X PBS, neutralized to 
pH7.4 and allowed to gel at 37’C in room air. 2 days after cell colonies have attached 
and spread out as a monolayer, a second layer of gel was added to form a sandwich 
gel culture. Medium for bile duct differentiation was constituted with Williams E with 
50% conditioned medium and supplemented with 100nmol/l insulin, 5µmol/l 
hydrocortisone, 10ng/ml EGF (BD Biosciences,Bedford, MA), antibiotics and daily 
pulse of 20ng/ml FGF. Medium was changed every 3 days. 
 
8.1.7  Fat differentiation 
To induce fat differentiation, cells were cultured on collagen at a density of 1X104 
cells/cm2. Adipogenic medium consisted of Dulbecco’s Modified Eagle Medium 
(DMEM) (Low glucose) supplemented with 0.5 mmol/L 3-isobutyl-1-methylxanthine, 
1 µmol/L hydrocortisone, 0.1 mmol/L indomethacin, and 10% horse serum and was 
changed twice weekly. Adipogenesis was determined by Oil Red O staining and RT 
PCR for human PPARγ2.  
 
8.1.8  Osteogenic Differentiation.  
Osteogenic differentiation was induced with DMEM(High glucose) supplemented 
with 0.1 µmol/L dexamethasone, 10 mmol/L -glycerol phosphate, and 0.2 mmol/L 
ascorbic acid, 10% FBS and antibiotics. Cells were cultured on fibronectin with 
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medium change every 3 days for period of 28days. Osteogenesis was assessed by  
osteopontin RT PCR and  von Kossa staining for calcium deposit. 
 
8.1.9 Chondrogenic Differentiation.  
Cells were centrifuged at 1000 rpm, 5 minutes, to form a pelleted micromass and 
cultured in suspension in polypropylene tube. Chondrogenic medium consisted of 
DMEM supplemented with 0.1µmol/L dexamethasone, 50µg/mL ascorbic acid, 
100µg/mL sodium pyruvate (Gibco/Invitrogen, Carlsbard, CA), 40µg/mL proline 
(Sigma-Aldrich), 10 ng/mL transforming growth factor-β3, and 50 mg/mL ITS+ 
(insulin, transferrin, selenium) premix (BD Biosciences, Bedford, MA). Medium 
changes were performed twice weekly, and chondrogenesis was assessed by 
histochemical staining for proteoglycans as well as immunohistochemical 
identification of cartilage specific type II collagen. 
 
8.1.10 Endothelial Differentiation 
Endothelial differentiation was induced with DMEM (High glucose) supplemented 
with 10% FBS, antibiotics and PDGF-CC91 (10 ng/ml) in fibronectin substrate. 
Medium was changed every 2 days and cells tested for presence of CD31 and vWF by 
immunofluorescence after 9 days  of induction. 
 
8.2 Characterisation of Fetal Liver Progenitor cells. 
8.2.1 Immunohistochemistry and Immunofluorescence 
 Progenitor  cell colonies were treated with 0.25% trypsin to remove feeder layers, 
harvested and frozen in  OCT (Electron Microscopy Sciences, Fort Washington, PA). 
All other monolayer cells were cultured in lab-tek slide chambers and processed fresh. 
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Sections for immunofluorescence were fixed with 3.5% cold paraformaldehyde for 5 
mins, -20’C methanol for 2 mins followed by 0.5mM glycine to reduce 
paraformaldehyde fluorescence.  Slides for immunohistochemistry were fixed with  
1:1 volume mixture of -20’C methanol/acetone followed by  0.3% H2O2 to block 
endogenous peroxidase. Sections were then blocked with appropriate serum (2% to 
10%) for 30 minutes. Primary antibodies against human antigens were applied to 
slides for 1 hour at room temperature and they include anti-albumin (ICN 
Pharmaceuticals, Aurora, OH), -fetoprotein,  CK7, vWF (Dako Cytomation, Inc., 
Carpinteria, CA), 1-antitrypsin (1AT),  vimentin (Sigma Aldrich Co. St. Louis, 
MO), CD44h (Hybridoma bank, University of Iowa), cmet, ckit(R&D Systems, Inc., 
Minneapolis, MN) , CD34, CD31-phycoertythin conjugated, CD105 and CD90 (Thy-
1) (BD BioSciences/Pharmingen, Franklin Lakes,NJ), EPCAM (Oncogene Research 
Products,Boston, MA)  SSEA-4, cytokeratin 18 (ICN Pharmaceuticals), CK19 
(Amersham, Buckinghamshire, England). For immunohistochemistry, Horseradish 
peroxidase–conjugated anti-mouse, anti-rabbit and anti goat  antibodies (all from 
Vector laboratories, Burlingame, CA)  served as secondary antibodies with positive 
detection based on reaction with 3,3-diaminobenzidine tetrahydrochloride. 
Fluorescent detection was by Alexa Fluor® 488 or Alexa Fluor® 594 conjugated 
secondary antibodies (Molecular probes/Invitrogen, Carlsbad,CA). Nuclei were cross 
stained with 4',6-Diamidino-2-phenylindole (DAPI). Specificity was confirmed using 
immunoglobulin G–specific controls. Cell morphology  were studied with Nikon 
Inverse phase contrast microscope and immunofluorescence was captured by Nikon 
Eclipse 600 immunofluorescent microscope or confocal Leica TCS SP/NT on an 
DMIRBE inverted microscope. Percentage of positive cells was determined by 
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manual counting of positive immunofluorescent cells to DAPI positive nucleus in 3 
separate random fields (at 40X magnification objective) on the Nikon microscope. 
 
8.2.2 Histochemistry 
Periodate-Schiff technique was performed according to that described by 
McManus.160  GGT assay was performed according to the method of Rutenburg.134 
Bony calcification was detected by von Kossa stain while cartilage specific 
proteoglycans were stained with sofranin-O and fast green stain.  
 
8.2.3 Transmission Electron Microscopy  
Specimen preparation for electron microscopy used standard techniques. Cells grown 
in standard culture dishes were fixed with Karnofsky’s fixative and postfixed in 1% 
osmium tetroxide before dehydration and embedding in Epon.  
 
8.2.4 Enzyme-Linked Immunosorbent Assay  
Human albumin concentrations from culture media were measured by the sandwich 
enzyme-linked immunosorbent assay as previously described.50 The lower limit of 
sensitivity of the human albumin assay was 15 pg/mL and was linear up to 1,000 
µg/mL. The capture antibody (goat anti-human antibody; 4 µg/mL), the detection 
antibody (peroxidase-conjugated goat immunoglobulin G fraction to human albumin; 
3 µg/mL), and the purified human albumin standards were purchased from ICN 
Pharmaceuticals (Durham, NC). 
 
8.2.5 RTPCR  
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Using Trizol reagent (Ambion, Austin, TX), total RNA was isolated from P3-P5 
colonies of hFLMPC, partially differentiated hepatocytes at D3 of differentiation 
protocol, differentiated hepatocytes at D20 of differentiation protocol and cells treated 
with 21 days of adipose or bone induction. One g of RNA was reverse transcribed 
(Ambion Retroscript kit), and RT-PCR was used to determine expression of several 
genes using specific primer pairs (see table 2).  In all cases, PCR cycle analysis was 
first performed to determine the linear range of each amplicon for a given primer pair. 
Expression levels of each gene were normalized to that of -actin or 18S ribosomal 
subunit as described in the Quantum RNA kit (Ambion).    
  
8.2.6 Western Blot 
 Protein cell lysates and immunoblotting were performed as previously described.161 
Antibodies used were similar to those used for immunostaining as described above. β-
actin (Sigma-Aldrich, St Louis MO) served as a loading control. Antigen-antibody 
complexes were detected with the appropriate horseradish peroxidase–conjugated 
secondary antibody and enhanced chemiluminescence (Santa Cruz Biotechnology, 
Santa Cruz,CA). Semi-quantitaion of bands, where relevant, was performed using 
ImageQuant™ TL software (GE Healthcare Technologies,Waukesha, WI) 
 
8.2.7 Cytochrome P450 Assay 
Cytochrome P450 Cy2B6 was induced in cells by adding  phenobarbitone 2µM to 
culture medium for 72 hours. Cy2B6 activity was tested by incubating cells with 5uM 
Pentoxyresorufin  O Dealkylase assay (PROD), with 20uM dicumerol (all from 
Sigma-Aldrich, St Louis, MO) and DMEM without phenol red for 30 mins.  The 
amount of resorufin fluorescence was read with an excitation wavelength of 530 nm 
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and an emission wavelength of 590 nm using Packard Fluorocount (Packard 
Instrument Co., Meriden, CT) using reference standards of 5nM to 1200nM resorufin. 
(Molecular probes, Carlsbad,CA). PROD activity was then normalized to protein 
concentration and expressed as per microgram/ml of protein. 
 
8.2.8 Cell Proliferation Assay and Doubling Time 
Bromodeoxyuridine (BrdU) (Roche Diagnostics Corp, Indianapolis, IN) was added to 
cells at  final concentration, 10 umol/L for 48 hours. BrdU labeling was then 
determined by immunohistochemistry using anti BrdU Clone 20U (Dako Cytomation, 
Inc., Carpinteria,CA)   
 
8.2.9 Cell doubling and growth curve.  
Progenitor cells were cultured in 48 well plates with feeder layers. Cells were 
incubated with 100ul of solution containing 1mg/ml of XTT, 7.5 ug/ml phenazine 
methosulfate (all from Sigma Aldrich Co. St. Louis, MO) and phenol red free 
DMEM, every day for 30mins. The assay is based on the conversion of the yellow 
tetrazolium salt XTT into an orange formazan dye by metabolically active cells and 
has been previously shown to be linearly related to the number of cells.162 Activity 
due to progenitor cells as measured using BIORAD Smartspec 3000 at A450nm (Bio-
Rad laboratories., Hercules, CA),   was   calculated from  XTT(hFLPC+ Feeder layer) 
– XTT(Feeder layer only) from triplicate experiments. Log values were then plotted 
against time to obtain growth curve from which doubling time was derived 
 
8.2.10 Telomere Length Determination 
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Telomere length assay was performed on D4 primary fetal hepatocyte, P1, P10 and 
P20  progenitor  cells using TELOTAGGG telomere length assay (Roche Diagnostics 
Corp, Indianapolis, IN ) according to manufacturer’s instructions.  
 
8.2.11 Cell labeling for origin of fetal liver progenitor cells 
Cells were transfected with GFP using lentiviral vectors of up to 90% efficiency. To 
determine origin of fetal progenitor cells, fetal liver was dissociated and parenchymal 
and mesenchymal stem cell fractions were separated using percoll density 
centrifugation.157-158 Purity of parenchymal  and mesenchymal cells was determined 
by random sampling and counting albumin and CD44 immunofluorescence 
respectively. Purity was in excess of 90% in both fractions.  GFP transfected 
parenchymal fraction were then cocultured back with unlabelled non-parenchymal 
fraction and GFP transfected mesenchymal stem cells were similarly cross cultured 
with unlabelled primary fetal hepatocytes. Progenitor cells were derived 3 months 
later and expression of GFP was determined in these cells. 
 
8.2.12 Determination of cell clonality 
Clonality of progenitor cells was determined using the Humara Assay as described 
based on concept of random X chromosome inactivation.132 PCR was first performed 
to select progenitor cultures that were from females heterozygous for Humara allele. 
Clones were then derived and DNA isolated from P3-5 colonies. 1ug of DNA were 
digested with Hha I (Promega Corp. Madison, WI) in accordance to manufacturer’s 
instructions. Nested PCR was then performed as previously reported.163 PCR products 
were ran on 6% polyacrylamide gels and visualized with ethidium bromide to 
determine if samples had non-random X inactivation, and hence were clonal.    




8.3 In vivo Transplantation 
4- to 6-week-old Rag2−/−γc−/− mice137(C57BL/6J × C57BL/10SgSnAi)-[KO]gc-
[KO]Rag2; Taconic Farms) were used for in vivo transplantation of hFLMPCs and 
maintained in accordance with animal care protocols. All mice were treated with 
weekly retrorsine (60 mg/kg i.p.) for 3 weeks to inhibit replication of native 
hepatocytes. Three mice then underwent intrasplenic injection with enriched fetal 
liver progenitor cells (3 × 106 cells); the remaining three mice underwent a sham 
operation (laparotomy). i.p. carbon tetrachloride (0.5 ml/kg diluted 1:10 in olive oil) 
was injected 1 week later and repeated weekly for 2 more weeks in all mice, and all 
were harvested 4 weeks after transplantation. Expression of human albumin was 
determined by serum ELISA, RT-PCR. 
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Little is known about the differentiation capabilities of nonhema-
topoietic cells of the human fetal liver. We report the isolation and
characterization of a human fetal liver multipotent progenitor cell
(hFLMPC) population capable of differentiating into liver and
mesenchymal cell lineages. Human fetal livers (74–108 days of
gestation) were dissociated and maintained in culture. We treated
the colonies with geneticin and mechanically isolated hFLMPCs,
which were kept in an undifferentiated state by culturing on
feeder layers. We derived daughter colonies by serial dilution,
verifying monoclonality using the Humara assay. hFLMPCs, which
have been maintained in culture for up to 100 population dou-
blings, have a high self-renewal capability with a doubling time of
46 h. The immunophenotype is: CD34, CD90, c-kit, EPCAM,
c-met, SSEA-4, CK18, CK19, albumin, -fetoprotein,
CD44h, and vimentin. Passage 1 (P1) and P10 cells have identical
morphology, immunophenotype, telomere length, and differenti-
ation capacity. Placed in appropriate media, hFLMPCs differentiate
into hepatocytes and bile duct cells, as well as into fat, bone,
cartilage, and endothelial cells. Our results suggest that hFLMPCs
are mesenchymal–epithelial transitional cells, probably derived
from mesendoderm. hFLMPCs survive and differentiate into func-
tional hepatocytes in vivo when transplanted into animal models
of liver disease. hFLMPCs are a valuable tool for the study of human
liver development, liver injury, and hepatic repopulation.
epithelial–mesenchymal transition  liver differentiation 
liver progenitor cell
The potential applicability of the transplantation of hepato-cytes or liver progenitor cells for the treatment of liver
diseases has received much attention. Central to the success of
this approach is an understanding of hepatic cell lineages and the
main steps that give rise to hepatocytes during embryonic
development. Liver progenitor cells persist in the adult rodent
liver in the canals of Hering (1, 2). These progenitor cells give
rise to oval cells, which can generate both hepatocytes and biliary
epithelial cells when hepatocytes are unable to mount a prolif-
erative response to injury (3–5).
In rodents, there has been considerable success in isolating
precursor cells from the fetal liver and liver epithelial cells or
oval cells from adult liver (5–7). Suzuki et al. (8, 9) isolated a
mouse fetal liver stem cell (c-metCD49FCD29
CD45CDTER119) that not only differentiated into hepa-
tocytes and bile duct cells but also was capable of differentiating
into intestinal and pancreatic epithelial cells. In humans, isola-
tion of liver stem cell lines has proven more difficult, and to date
no unmodified human embryonic liver progenitor cell lines have
been reported (10).
Given the diversity of potential hepatoblast precursors de-
scribed in the mouse, we hypothesized that the human fetal liver
might contain intermediate cells in the differentiation pathway
from endoderm to hepatoblast. We report here the isolation and
characterization of a stable population of human liver progenitor
cells from the human fetal liver that does not express liver-
specific genes but is able to differentiate into functional hepa-
tocytes and bile duct cells. Of great interest is that these cells,
which we named human fetal liver multipotent progenitor cells
(hFLMPCs), have features of mesenchymal–epithelial transi-
tion; retain multipotent capability to differentiate into fat,
cartilage, bone, and endothelial cells; and have repopulation
capacity in a mouse model of liver injury.
Results
Derivation of hFLMPCs. In our previous work with primary human
fetal hepatocyte cultures, we observed a subpopulation of small
blast-like cells that were highly proliferative and expressed
markers of liver progenitor cells (11). To isolate and characterize
hFLMPCs, we used seven liver specimens obtained from legally
aborted first- and second-trimester fetuses between 74 and 108
days of gestation. Using the method described (11), we main-
tained cells from these livers in primary culture for 3 months to
allow enrichment of blast-like cells until they formed a uniform
layer over the multilayered cell cultures. Calibrated doses of
geneticin were used on passaged cells to selectively arrest
fibroblast growth, allowing the proliferating progenitor cell
colonies to be mechanically isolated onto feeder layers. We were
able to derive hFLMPC colonies from five of seven fetal liver
specimens (see Table 1, which is published as supporting infor-
mation on the PNAS web site). Clones were further derived by
serial dilution and maintained for up to 6 months (100 popula-
tion doublings, 20 passages).
Characterization of hFLMPCs. hFLMPCs grow in a 3D fashion
similar to human ES cells (Fig. 1A). They are small cells
averaging 10m in diameter with scanty cytoplasm (Fig. 1B).We
confirmed that the hFLMPC colonies we derived were clonal by
using the Humara X assay. Using an inactivation ratio 0.4
(12–14), all three colonies derived from a heterozygous female
specimen (no. 18849) showed nonrandom skewed inactivation
of the unmethylated Humara X allele (Fig. 1C), confirming
clonality.
hFLMPCs Have Self-Renewal Properties Without Evidence of Telomere
Shortening.One of the key characteristics of a stem cell population
is its ability to self-regenerate. hFLMPCs have an estimated dou-
bling time of 46 h by the 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-
5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide (XTT) assay
(Fig. 1D) and demonstrate high BrdU incorporation (see Fig. 7,
which is published as supporting information on the PNAS web
site). The morphology, immunophenotype, and differentiation
potential are identical among hFLMPCs from different passages
(data not shown). Cells from P1, P5, and P20 cultures had similar
average telomere length that did not shorten, even after 100
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population doublings (Fig. 1E), suggesting that their self-
regenerative potential is durable.
Immunophenotype of hFLMPCs. To determine the immunopheno-
type of hFLMPCs, we used immunofluorescence or immuno-
histochemistry, with confirmation by either RT-PCR (when
confirming negativity) or immunoblotting (when confirming
positivity). hFLMPCs are positive for CD34 (Fig. 2A), CD90
(thy-1), c-kit, and SSEA-4 (see Fig. 7). These markers are
consistent with a stem-cell signature (15) and have been reported
in mouse liver progenitor cells (16). hFLMPCs are also positive
for epithelial markers such as EPCAM (Fig. 2B), CK18 (Fig.
2C), and CK19 (Fig. 2D). CK18 and -19 are characteristic
markers of hepatocytes and bile duct cells, respectively. Inter-
estingly, hFLMPCs are also positive for the mesenchymal mark-
ers CD44h (Fig. 2E) and vimentin but are negative for other
mesenchymal cell markers, including CD105, CD73, and SMA
(data not shown). Hematopoietic markers such as CD45 and
AC133 are also negative (data not shown). hFLMPCs are
positive for c-met (Fig. 2F) but did not express liver-specific
markers such as albumin (Fig. 2G), -fetoprotein (FP; Fig. 2H),
or the ‘‘liver specification’’ transcription factors hepatocyte
nuclear factor (HNF)1, HNF3, and HNF4 (Fig. 4B).
hFLMPCs are thus a progenitor population within the fetal liver,
expressing mixed mesodermal and endodermal markers.
Are hFLMPCs Derived from Other Cells in Fetal Liver Culture? To
determine the origin of hFLMPCs, we performed lineage tracing
by selective labeling of subpopulation fractions within initial
fetal hepatocyte cultures and subsequently deriving hFLMPC
colonies (see Fig. 8, which is published as supporting information
on the PNAS web site). In cultures in which parenchymal fetal
hepatocytes had been GFP-labeled, none of eight derived
hFLMPC colonies were GFP-positive. Similarly, in cultures in
which mesenchymal stem cell (MSC) fractions were GFP-
labeled, none of the six derived hFLMPC colonies were GFP-
positive. These results suggest that hFLMPCs are a distinct
population in the fetal liver and are unlikely to arise from
dedifferentiating parenchymal hepatocytes or transdifferentiat-
ing MSCs.
hFLMPCs Are Progenitor Cells for Hepatocytes and Bile Duct Cells.
When grown on collagen plates, hFLMPCs flatten into a mono-
layer, progressively increase in size, and assume a polygonal
morphology characteristic of hepatocytes (Fig. 3A). Differenti-
ated cells start expressing albumin on day 3 (D3), with 96% of
cells becoming strongly positive by D21 (Fig. 3B). FP expres-
sion transiently appears at D3–D4 but is no longer detectable by
D21 (see Fig. 9, which is published as supporting information on
the PNAS web site). These trends were corroborated by immu-
noblot and RT-PCR (Fig. 4). Correspondingly, albumin in the
culture medium was undetectable by ELISA at D0 but increased
to 180 ngml at D5 and 1.2 gml at D15 (Fig. 3C). Differen-
tiated cells store glycogen within the cytoplasm (Fig. 3D), and
electron microscopic analysis reveals a cytoplasmic organization
characteristic of hepatocytes and the formation of bile canaliculi
between neighboring cells (Fig. 3E). These cells also express
-1-antitrypsin (Fig. 4; also see Fig. 9), and liver-specific cyto-
chrome P450 enzymes inducible by phenobarbital (see Fig. 9).
Cytochrome 3A4 production increased 1.6 (immunoblot den-
sity quantitation), whereas cytochrome 2B6 activity [pen-
toxyresorufin-O-depentylase (PROD) assay] was up-regulated
1.4 after phenobarbital treatment. The liver-specific transcrip-
tion factors HNF1, HNF3, and HNF4, which are not de-
tectable in hFLMPCs, are expressed in differentiated hepato-
cytes (Fig. 4). Taken together, our data indicate that hFLMPCs
can differentiate into functional hepatocytes. These hepatocytes
decrease in proliferation upon differentiation but can be main-
tained in continuous culture up to 6 weeks.
When grown on 3D collagen sandwich gels, hFLMPCs rear-
range into cystic and tubular structures by D5 (Fig. 3F and see
Fig. 9), with cells lining the lumen assuming a columnar shape
with tight junctions. Electron microscopy demonstrates long
parallel microvilli on the luminal surface of these cells, typical of
biliary epithelial cells (Fig. 3G). These cells are uniformly
positive for markers of biliary cells, including GGT (Fig. 3H),
CK7 (Fig. 3I), and CK19 (Fig. 3J).
Expression of Both Mesenchymal and Epithelial Markers in hFLMPCs.
hFLMPCs express both epithelial and mesenchymal cell mark-
ers. We used immunofluorescence colabeling to determine
whether these makers are coexpressed in the same cells, and if
so, whether these markers change when hFLMPCs differentiate
into hepatocytes. hFLMPCs coexpress both epithelial and mes-
enchymal markers within the same cell (see Fig. 10, which is
published as supporting information on the PNAS web site), and
as the expression of liver-specific proteins like albumin increases,
mesenchymal markers such as vimentin and CD44h are down-
regulated and disappear altogether with complete hepatocyte
differentiation. This phenotypic change is characteristic of mes-
Fig. 1. hFLMPC cultures. (A) Phase-contrast micrograph. hFLMPCs grow in
heaped-up clusters on NIH 3T3 feeder layers. (B) Electron micrograph.
hFLMPCs have a high nuclear to cytoplasm ratio with scanty organelles in the
cytoplasm and absent bile canaliculi. (C) Humara X nested PCR for clonality.
Specimen no. 18849 was heterozygous for the Humara X allele (control lanes).
DNA extracted from clones 1–3 derived from no. 18849 was subjected to
digestion by HhaI () or without HhaI (). The allele inactivation ratios
(density ratio of least-intense band to more-intense band, before compared
with after digestion) were 0.4 for all three clones, indicating clonality. (D)
Growth curve of hFLMPCs as determined by XTT activity, revealing a doubling
time of 46 h. Proliferation decreases after 10 days as the irradiated feeder layer
starts to degenerate. (E) Telomere length assay by Southern blotting. Fresh
fetal hepatocytes. P1, P5, and P20 hFLMPCs show no apparent shortening of
average telomere length, even after 100 population doublings.














enchymal–epithelial transition and suggests that hFLMPCs rep-
resent transitional cells between mesenchymal and endodermal
lineages.
hFLMPCs Have the Developmental Capacity of MSCs. In view of the
expression of mesenchymal markers by hFLMPCs, we investi-
gated whether these cells have the capacity to develop into
mesenchymal lineages. In adipose inductionmedia, cells increase
in size, and 40% accumulate coalescing vacuoles that stain
positive for fat (Oil red O), as opposed to differentiated hepa-
tocytes, which do not survive in fat induction medium. These
fat-like cells also express peroxisome proliferator-activated re-
ceptor 2, in contrast to hFLMPCs and differentiated hepato-
cytes, which do not (Fig. 5 A and B). In contrast, differentiated
hepatocytes do not survive in fat induction medium. Maintained
in bone inductionmedium, cells become elongated with irregular
processes, deposit calcium (von Kossa stain), and express os-
teopontin mRNA (Fig. 5 C and D). In cartilage induction media,
cell clusters form a matrix core containing glycosaminoglycans,
which stain positive for safraninO and cartilage-specific collagen
type II (Fig. 5 E and F). In endothelium induction medium
containing platelet-derived growth factor (PDGF)-CC (17),
hFLMPCs become spindle-shaped and express the endothelial
markers CD31 (28%; data not shown) and vonWillebrand factor
(38%; Fig. 5 G and H). hFLMPCs can clearly behave like MSCs
and, with appropriate stimulation, can give rise to each of the
mesenchymal lineage-like cells.
hFLMPCs Can Give Rise to Functional Hepatocytes in Vivo. To deter-
mine whether hFLMPCs can function as hepatocytes in vivo, we
transplanted enriched hFLMPCs into immunotolerant Rag2/
c/ mice (18) by using a modified retrorsinecarbon tetra-
Fig. 2. Characterization of hFLMPCs. (A–E) Immunofluorescence and (F–H) immunohistochemistry. hFLMPCs are positive for stem cell markers such as CD34 (A);
epithelial markers such as EPCAM (B), CK18 (C), and CK19 (D); and mesenchymal markers such as CD44h (E). They are also positive for c-met (F) but do not express
liver-specific markers such as albumin (G) or FP (H).
Fig. 3. hFLMPCs are progenitors of hepatocytes and bile duct cells. (A) Phase-contrast micrograph. When cultured without feeder layers, hFLMPCs flatten and
increase in size to become polygonal cells characteristic of hepatocytes. (B) Immunofluorescence. Ninety-five percent of cells at D21 of hepatocyte differentiation
are positive for albumin. (C) ELISA for human albumin in media increases progressively from D3. (D) Differentiated hepatocytes express glycogen deposits (PAS
stain). (E) Electron micrograph. Differentiated hepatocytes show characteristic formation of bile canaliculi (red arrow). (F) Phase-contrast micrographs. When
cultured in collagen sandwich gels, hFLMPCs assume a cystic and tubular ductal morphology. (G) Electron micrograph. Parallel villi characteristic of biliary
epithelial cells are shown. These cells were positive for GGT (H, histochemistry), CK7 (I, immunofluorescence), and CK19 (J, immunofluorescence).
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chloride model (19). Three of three mice killed 30 days after
transplantation had human-specific albumin in the serum (Fig.
6A) and expressed human-specific albumin in the liver (Fig. 6B).
Liver sections of transplanted mice demonstrated clusters of
morphologically larger cells (Fig. 6C), which stain positive for
human-specific albumin (Fig. 6D). The degree of repopulation is
estimated to be 0.8–1.7% in these mice. These data indicate that
hFLMPCs can differentiate into functioning hepatocytes and
integrate into the liver parenchyma in an in vivo injury model.
Discussion
We report the isolation and characterization of cells from the
human fetal liver (hFLMPCs) that are capable of differentiating
into hepatocytes and bile duct cells as well as into mesenchymal
lineages, including adipose tissue, bone, cartilage, and endothe-
lium. hFLMPCs have a high self-renewal capacity and showed no
telomere shortening after 100 population doublings. These cells
are discernible as a distinct population at the onset of primary
cultures and are highly proliferative (11). Based on our data from
mixing experiments with GFP-labeled hepatocytes or MSCs, it
is unlikely that hFLMPCs are derived from either of these cell
types in culture. Thus hFLMPCs are a unique cell type with stem
cell characteristics. To our knowledge, the establishment of
clonal cells from human liver that can be maintained in long-
term culture in an undifferentiated state and in which directed
differentiation to liver and mesenchymal lineages can be con-
trolled at will, has not been previously described.
Although hFLMPCs readily differentiate into hepatocytes and
bile duct cells, we did not detect expression of albumin, FP, or
the transcription factors HNF1, HNF3, and HNF4 in their
undifferentiated state, indicating that these cells are either
prehepatoblasts or liver progenitor cells from a parallel differ-
entiation pathway. hFLMPCs coexpress epithelial and mesen-
chymal markers, and in view of their ability to generate both liver
cells and mesenchymal lineages, we consider hFLMPCs to be
mesenchymal–epithelial transitional cells and suggest that they
have a mesendodermal origin.
It has been hypothesized that mesoderm and endoderm arise
from a common bipotential mesendoderm precursor (20). Trem-
blay and Zaret (21) demonstrated that cells from the ventral
midline of the endoderm lip, probably originating from the
mesendodermal prechordal plate, give rise to part of the liver
bud. Elsewhere in the animal kingdom, 80% of the turtle liver is
apparently derived from the mesenchyme (22). Additionally,
multiple studies have shown that MSCs or mesoderm-related
multipotent adult progenitor cells in both mice and humans can
differentiate into hepatocytes (23, 24). hFLMPCs appear to have
mesendodermal origin, but further fate-map analysis and char-
acterization of liver specification profiles will determine whether
they arise from the cells described by Tremblay and Zaret (21)
or are from a distinct progenitor niche. Mesenchymal–epithelial
Fig. 4. Expression patterns of hFLMPCs and differentiated hepatocytes. The
immunophenotypes of hFLMPCs and differentiated hepatocytes (D3 and D21)
were confirmed with immunoblotting (A) and RT-PCR (B). Albumin, FP, and
-1-antitrypsin protein are not expressed in hFLMPCs but appear with hepa-
tocyte differentiation. This expression pattern for albumin and FP is further
confirmed with RT-PCR. Similarly, HNF transcripts, including HNF1, HNF3,
and HNF4, were absent in hFLMPCs but are present in differentiated hepa-
tocytes. Dx Hep, differentiated hepatocytes; ctrl, positive control.
Fig. 5. hFLMPCs have the developmental capacity of MSCs. (AandB) Adipose
tissue induction. hFLMPCs increased in size (A) and accumulated vacuoles that
stained positive for fat (B, Oil red O stain, 40% of cells) and expressed
peroxisome proliferator-activated receptor-2 (RT-PCR). (C and D) Bone in-
duction. hFLMPCs assume a longitudinal and interwoven conformation (C);
deposit calcium into the extracellular matrix, which stains black with von
Kossa stain (D); and maintain expression of osteopontin (RT-PCR). (E and F)
Cartilage induction. hFLMPC cultures in suspension form a ringed cluster with
extracellular matrix in the middle that stains pinkish red with Safranin (E) and
is positive for collagen II (F, red immunofluorescence with blue DAPI nuclear
stain). (G andH) Endothelium induction. (G) hFLMPCs become spindle-shaped
with formation of linear channels between cells. (H) Thirty-eight percent of
cells are positive for von Willebrand factor (red immunofluorescence with
blue DAPI nuclear stain).














transitional cells are not uncommon in fetal development (25)
and have been demonstrated in both rodent neonatal (26) and
fetal livers (27), as well as human fetal livers, in which they have
been reported to support hematopoiesis (28).
hFLMPCs are clearly different from MSCs or multipotent
adult progenitor cells, as described by Jiang et al. (29). Their
morphology, inherent epithelial markers, and potential to spon-
taneously become hepatocytes set them apart from MSCs trans-
differentiating into epithelial lineages. In our liver differentia-
tion protocols, MSCs from the same fetal livers were used as
controls, and they did not become hepatocytes or bile duct cells.
Interestingly, hFLMPCs share some morphologic and immuno-
phenotypic characteristics of epithelial cells isolated from pa-
tients with subacute hepatic failure (30) and other hepatic
diseases (31). They also appear to be similar to bipotential mouse
embryonic liver (BMEL) progenitor cells isolated from mouse
fetal liver (32). hFLMPCs are derived differently, however, and
appear to have a mixed mesendodermal origin rather than the
hepatoblast origin of BMEL cells.
In conclusion, we believe we have isolated and characterized
human fetal liver progenitor cells with multipotent differentia-
tion potential. hFLMPCs appear to have durable proliferative
capability and can be induced to differentiate into functional
hepatocytes and biliary duct cells in vitro, even after being kept
in culture for 6 months. They can differentiate into functional
hepatocytes in vivo, suggesting liver repopulation potential. We
are currently investigating the critical factors that determine
their differentiation, proliferation, and lineage transition, as well
as the optimal conditions for maintaining differentiated hepa-
tocytes in culture for longer periods of time. We are also
exploring the use of this approach to isolate similar cell popu-
lations from other embryonic organs, such as pancreas and
kidney. We anticipate that hFLMPCs will be a valuable tool to
study differentiation pathways in the human liver and may have
important therapeutic applications in patients with liver failure.
Materials and Methods
Materials. Basic culture media were purchased from Gibco
Invitrogen; supplements and chemicals were from Sigma Al-
drich, unless otherwise specified.
Source and Isolation of hFLMPCs.Human fetal livers were obtained
from the Central Laboratory for Human Embryology at the
University of Washington, in accordance with a protocol ap-
proved by the Institutional Review Board. Primary fetal hepa-
tocyte cultures were raised and maintained in human fetal
hepatocyte medium, as described (11).
Cultures were maintained for at least 3 months to allow
enrichment of small blast cells before passage with 1 mgml
collagenase (Boehringer Ingelheim) and 10 unitsml dispase
(BD Biosciences, Franklin Lakes, NJ). Geneticin (50 ngml;
GibcoInvitrogen) was added to culture media immediately
after passage and maintained for 6 days. Colonies of hFLMPCs
were then mechanically isolated with microscopic guidance and
transferred onto hFLMPC culture plates.
Culture and Cloning. hFLMPCs were cultured on irradiated NIH
3T3 feeder layers (180,000 cellsml; American Type Culture
Collection, Manassas, VA) in plates coated with collagen (Vitro-
gen, Collagen Corp.)laminin substrate, maintained with 50%
human fetal hepatocyte medium without dexamethasone, 20%
FBS, and 30% conditioned medium. Conditioned medium was
taken from primary fetal hepatocyte cultures (at least 3 months
old) every 48 h and filtered before use. The medium was further
supplemented with basic FGF (10 ngml) and complex fatty
acids (5 mlliter). Media were changed daily and cultures
maintained at 37°C with 6% CO2. Cloning was performed by
serial dilution, and daughter colonies were derived from single-
or two-cell clusters on feeder layers, as witnessed under an
inverse microscope. Colonies were then passaged every 10 days
by using a cut-and-paste technique, as used in human ES cell
culture protocols (33).
In Vitro Differentiation Protocols. All differentiation protocols
were performed in triplicate with P1–P4 and P8–P12 hFLMPC
colonies. Percoll gradient separation was used to isolate human
fetal MSCs (34) and parenchymal primary fetal hepatocytes (35)
for use as controls. Details of the differentiation protocols are
outlined in Supporting Text, which is published as supporting
information on the PNAS web site.
Characterization of Cells. Immunofluorescence, immunohisto-
chemistry, histochemistry, immunoblotting, RT-PCR, electron
microscopy, XTT assay (36), BrdU labeling, and cytochrome
P450 assays were based on standard protocols (see Supporting
Text).
Telomere Length Determination. Telomere length was determined
in D4 primary fetal hepatocytes and P1, P10, and P20 hFLMPCs
by using the TELOTAGGG telomere length assay (Roche
Diagnostics) according to the manufacturer’s instructions.
Cell Labeling to Determine Origin of hFLMPCs. To determine the
origin of hFLMPCs, parenchymal and MSC fractions from fetal
liver were separated by using Percoll density centrifugation (34,
35). The purity of parenchymal and MSC fractions was deter-
mined by immunofluorescent expression of albumin or CD44h
in random samples of cell fractions in culture at D1 after
separation and was 90% for both fractions (data not shown).
Parenchymal and MSC subpopulations were separately trans-
Fig. 6. In vivo transplantation of hFLMPCs into Rag2/c/mice. (A) ELISA
for human-specific albumin is positive in serum from mice transplanted with
hFLMPCs but not in that of control (sham-operated) mice. (B) RT-PCR for
human albumin. Livers from transplanted mice express human-specific albu-
min, in contrast to control mice. This hematoxylineosin-stained liver section
from a mouse transplanted with hFLMPCs shows a cluster of morphologically
different hepatocyte-like cells (C), which stain positive for human-specific
albumin by immunofluorescence (D). The repopulation ratio is estimated to be
0.8%, 1.4%, and 1.7% for the three transplanted mice.
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fected with GFP-labeled lentiviral vectors driven by the EF1
promoter (37, 38) with up to 90% efficiency. Primary hepatocyte
cultures were then reconstituted by mixing labeled and nonla-
beled fractions, and the presence of GFP expression in derived
hFLMPC colonies was determined 3 months later (see Support-
ing Text and Fig. 8 for details).
Determination of Cell Clonality. Clonality of hFLMPCs was deter-
mined based on the concept of random X chromosome inacti-
vation by using the Humara assay, as described (39). Clones were
derived from a heterozygous female and DNA isolated from
P3–P5 colonies. One microgram of DNAwas digested with HhaI
(Promega) in accordance with the manufacturer’s instructions.
Nested PCR was then performed as reported (13). Densitomet-
ric analysis of ethidium bromide-labeled bands was performed by
using SCION IMAGE 4.03 software (Scion, Frederick, MD), and an
allele inactivation ratio of 0.4 was indicative of clonality
(12–14).
In Vivo Transplantation. Six 4- to 6-week-old Rag2//mice (18)
(C57BL6J  C57BL10SgSnAi)-[KO]gc-[KO]Rag2; Taconic
Farms) were used for in vivo transplantation of hFLMPCs and
maintained in accordance with animal care protocols. All mice
were treated with weekly retrorsine (60 mgkg i.p.) for 3 weeks to
inhibit replication of native hepatocytes. Three mice then under-
went intrasplenic injection with enriched hFLMPCs (3 106 cells);
the remaining three mice underwent a sham operation (laparot-
omy). i.p. carbon tetrachloride (0.5 mlkg diluted 1:10 in olive oil)
was injected 1 week later and repeated weekly for 2 more weeks in
all mice, and all were harvested 4 weeks after transplantation.
Expression of human albumin was determined by serum ELISA,
RT-PCR (seeTable 2, which is published as supporting information
on the PNAS web site), and immunofluorescence.
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Isolation and Expansion of EPCAM positive Progenitor cells from human Fetal 
Liver 
YY Dan, L Amer, LL Su, PC Wong, SG Lim 
 
Liver progenitor cells hold tremendous promise in their ability to provide a continual 
source of cells for wide variety of applications including cell therapy. Human liver 
progenitor cells are EPCAM positive but isolation and culture of these cells have 
proven difficult. We report the successful isolation and of EPCAM+ progenitor cells 
from the human fetal liver that can be expanded in in-vitro culture. 
 
Methods:13 and 18 weeks human fetal liver obtained from abortion under the purview 
of ethics board approval were treated with standard collagenase digestion. Cells were 
sorted using magnetic beads conjugated with anti-EPCAM antibody. Cultures were 
then performed on plates comparing various extracellular matrices including laminin, 
collagen, and matrigel, with and without feeder layers in chamber inserts setup. Cells 
were repeatedly passaged at confluence and purified with repeated EPCAM magnetic 
sorting. 
 
Results: EPCAM positive cells were successfully isolated with up to 97% purity by 
immunofluorescence sampling. They demonstrated 3 distinct phenotype characterised 
by progenitor (CK19+ CD44+, alb-, AFP-), bipotential progenitors (albumin+/AFP+ 
/CK19+) as well as a committed hepatoblast (albumin+ /AFP+/CK19-).  Laminin and 
matrigel plates together with conditioned media from EPCAM negative non-
parenchymal cell fraction of the same liver were critical for maintaining progenitor 
phenotype. These cells retained high nuclear-cytoplasmic ratio, had a doubling time 
of 42hours and could be expanded up to 6 passages in 3 months and could be scaled 
up with up to 100 fold expansion in numbers. On differentiation protocols, colonies of 
hepatocyte-like cells that were strongly albumin and glycogen positive were observed. 
On collagen gels, tubular structures were obtained that were positive for GGT and 
CK7. 
 
Conclusion: EPCAM positive cells select for progenitor cells that are hepatoblast and 
biliary progenitors. These cells can be maintained in their progenitor status with high 
and robust proliferative and expansion potential. Manipulation of culture environment 
can augment differentiation into both hepatocytic and biliary lineages. Current 
strategy is aimed at isolating subfraction of these cells. The ability to expand 
progenitor cells in in-vitro cultures holds promise in providing an additional source 
for hepatocytes for its many potential applications. 
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Long-Term Repopulation Potential Of Human Fetal Liver Progenitor Cells 
YY Dan, J Haque, J Campbell, SG Lim, NFausto 
 
Background and Aim: 
Liver stem cells hold great promise for  therapeutic cellular transplantation. Human 
fetal liver multipotent progenitor cells (hFLMPC) are unadulterated progenitor cells 
that can  proliferate and differentiate in vitro to become hepatocytes and bile duct 
cells. We studied their ability for long-term repopulation in animal models of liver  
 
Methodology 
Enriched hFLMPCs were obtained from 2nd trimester human fetal liver.  4 groups 
(n=3 x 4 vs controls) of Rag -/- γc mice pretreated with retrorsine were transplanted 
with 3 million progenitor cells and exposed to 3 weeks of intraperitoneal carbon 
tetrachloride. Mice were sacrificed at 1, 3, 6 and 9 months after transplantation. 
Human cells were identified with Immunofluorescence, Insitu-Hybridisation and 
mRNA analysis. 
  
Results:    
Quantitation studies  showed 0.7% to 2.6% to 0.8% and 0.2% repopulation at 1, 3, 6 
and 9 month respectively. This correlated directly with the human albumin mRNA as 
well as albumin concentration which  showed a peak at 3 months and decreased with 
time. Immunofluorescence  and  Insitu-hybridisation confirmed the human lineage of  
hepatocytes and isolated bile duct cells. They are functional, demonstrating  tight 
junction integration with   mouse hepatocytes and show no evidence of fusion or 




Human hepatocytes derived from hFLMPCs are able to survive, engraft, integrate as 
well as function in permissive mouse liver up to 9 months post transplant providing 
principle of proof of potential therapeutic benefit. The limitation of significant and 
highly variable  repopulation in a environment without extreme selection pressure 
continue to pose a challenge to their clinical usefulness.   
 
